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Introduction: Leptospirosis is a zoonosis caused by 19 genomospecies of pathogenic 
Leptospira requiring laboratory confirmation. Culture and microscopic agglutination test 
(MAT) are available only in reference centres, whereas molecular assays like PCR and 
LAMP are good alternatives. LAMP has been evaluated by only four research groups. 
Currently, most laboratories use IgM ELISA for diagnosis of leptospirosis.   
Objectives: To assess the usefulness of loop-mediated isothermal amplification (LAMP) 
assay, PCR and ELISA for the diagnosis of leptospirosis after validation of the ELISA.  
Materials and Methods: The diagnostic cut off for IgM ELISA was determined using 100 
plasma samples, 20 sera from healthy blood donors and serum samples from patients of scrub 
typhus with eschar (n=50), sepsis (n=20), enteric fever (n=20), dengue (n=17) and malaria 
(n=17). Three leptospira IgM ELISA kits (PanBio, Virion serion, Inbios) and IgG ELISA 
(Verion serion) were tested. After obtaining informed consent, 150 serum samples and 
clinical data were collected from adult patients (≥18 years) with acute undifferentiated fever 
(≥100º F) of duration ≤ 15 days without eschar, who were malaria and blood culture negative. 
The serum samples were tested for IgM antibodies to leptospira by PanBio ELISA. PCR for 
rrs gene and LAMP assay for LipL32 and LipL41 were performed on all the samples. 
Sequencing was done for 2 samples to assess amplification specificity. These samples were 
also tested for IgM antibodies to scrub typhus by ELISA (InBios). Convalescent sera could 
be collected from 32 patients and tested for IgM antibodies to leptospira. 
 
Results: The plasma and serum samples of the healthy blood donors showed similar results 
by ELISA. The cut-off determined for IgM ELISA by PanBio, InBios, Virion serion was ≥20 
PanBio units, ≥1 OD, ≥0.7 OD respectively, whereas it was ≥2.7 OD for Virion serion IgG 
ELISA. Among the 150 samples tested, three samples were positive by PCR, LAMP and IgM 
ELISA, two by only PCR, seven only by LAMP and 40 positive by IgM ELISA alone 
fulfilled modified Faine’s criteria. The LAMP assay was found positive in sera from patients 
with fever ≤7 days. BLAST analysis of the 2 sequenced PCR amplicons confirmed that the 
amplified DNA was Leptospira interrogans. Totally, 56 samples had IgM antibodies to scrub 
typhus of which 22 had IgM antibodies to both leptospira and scrub typhus. Decreased urine 
output, platelet count, severe jaundice and renal damage were significantly related to 
leptospirosis (p<0.5). Among the convalescent sera 10 patients continued to have IgM 
antibodies to leptospira. 
 
Conclusion:  LAMP assay is a reliable test for diagnosis of leptospirosis in the first week 
of illness whereas IgM ELISA forms the mainstay of diagnosis from second week onwards. 
Keywords: Leptospira, LAMP, PCR, ELISA, Validation 
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                                                       Introduction 
 
Leptospirosis is a zoonotic disease caused mainly by pathogenic species under the genus 
Leptospira (1). There are 20 genomospecies based on DNA hybridisation analysis among 
which L. interrogans, L. borgpetersenii, L. santarosai, L. noguchii, L. weilli, L. kirschneri 
and L. alexanderi are the main agents of leptospirosis in humans (2). Leptospira has 24 
serogroups and 250 serovars based on the surface exposed lipopolysaccharide (3). This 
infection is re-emerging in China, Japan, Australia, India and Europe. In India outbreaks have 
been reported from the Andamans, Tamil Nadu, Karnataka, Maharashtra, Andhra Pradesh 
and Orissa especially after heavy rains (4). 
Though most infections are subclinical or mild, severe disease does occur in 5-10% of 
patients and are associated with high mortality rate in this group (5). Majority of the patients 
present with non-specific symptoms of acute fever, headache, abdominal pain, myalgia and 
conjunctival suffusion, which makes it difficult to differentiate this illness from other causes 
of acute fever like scrub typhus, dengue and malaria (6). Thus laboratory confirmation of 
disease is important as clinical management is different for these conditions.  
Many diagnostic methodologies are available for laboratory diagnosis of this infection. Direct 
detection includes isolating the organism in culture or detecting specific DNA. In the first 
week the preferred specimen is blood whereas, from the second week onwards, urine is the 
specimen of choice as leptospiruria occurs (1). The use of culture as a diagnostic method is 
limited by its long turn over time, requiring at least 6-8 weeks for growth  (4). Dark field 
microscopy requires the presence of ≥104 organisms/ml as does detection of antigen in blood 
and urine by ELISA or RIA. In addition, dark field microscopy has a low sensitivity  (40.2%) 
and specificity (61.5%) compared to culture (7).  
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PCR targeting the 16S rRNA has been used to detect the presence of leptospires in serum, 
urine, CSF and autopsy tissue and has been found to be more sensitive than culture (1). Its 
value lies in the fact that it can diagnose the disease very early in the first week of illness 
before the appearance of antibodies and hence helps in early initiation of treatment.  
The genes commonly used for detection of leptospiral DNA by PCR are LipL32 coding for 
outer membrane lipoprotein LipL32 (8), rrs for 16S rRNA (9) and secY coding for pre-
protein translocase SecY protein (10). PCR is expensive and needs costly equipments, 
reagents and technical expertise. 
LAMP (loop-mediated isothermal amplification) is an alternative method of DNA 
amplification with high specificity, efficiency and occurs under isothermal conditions. It 
employs a DNA polymerase and a set of four specially designed primers that recognize six 
DNA sequences on the target DNA (11). The final products of LAMP are stem-loop DNAs 
with several inverted repeats of the target and cauliflower-like structures with multiple loops. 
These loops are formed by annealing between alternately inverted repeats of the target in the 
same strand. These help in simple, easy, selective detection by electrophoresis (5). The 
reaction results in the accumulation of huge amount of target and simply requires a laboratory 
water bath or heating block to maintain a constant temperature of 60–65°C. Detection of 
products is done by agarose gel electrophoresis, real-time monitoring in an inexpensive 
turbidometer or in the form of a colour change with an intercalating dye.  Moreover, the 
LAMP assay is not affected by polymerase inhibitors (12).   
The utility of LAMP for the rapid and specific diagnosis of leptospirosis has been evaluated 
by four different groups of researchers. Lin et al in 2009 developed a LAMP assay targeting 
the LipL41 gene and reported the lower detection limit of 100 genome equivalents similar to 
PCR in mouse kidney sample. The assay was easier and inexpensive compared to PCR (13). 
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Sonthayanon et al, developed another LAMP assay targeting the rrs gene and found the 
analytical sensitivity of 10 genome equivalents (6). They also performed clinical evaluation 
of the rrs LAMP and the LipL41 LAMP in blood samples. The sensitivity and specificity for 
rrs LAMP was 43.6% and 83.5% respectively while for the LipL41 LAMP the sensitivity and 
specificity was 37.6% and 90.2% respectively (6).  
Since leptospiral DNA has been detected from urine sample both in early and late disease by 
PCR compared to blood, Koizumi et al developed a rrs LAMP assay which can be used in 
heated urine samples (14).  The lower detection limit of the assay were 2 and 10 genome 
equivalents per reaction under heat-denaturing and non-denaturing conditions, and the 
performance of the assay was evaluated in urine of field mice. The assay was positive in 11 
of 12 culture positive boiled urine and in 10 of 11 culture positive urine pellet samples. The 
LAMP assay was also positive in two culture negative samples, suggesting a higher 
sensitivity than culture. As shedding of the leptospira occurs intermittently, the authors 
suggested repeated testing using nucleic acid amplification. 
Suwancharaoen et al evaluated the LAMP assay in 22 pathogenic and 2 non-pathogenic 
leptospira strains and found the sensitivity was better than PCR and specificity was excellent 
for pathogenic species of leptospira (15). 
MAT (microscopic agglutination test) is the reference method for serological diagnosis of 
leptospirosis. The presence of leptospiral antibody in the patient‟s serum is determined by 
incubating it with serogroup specific live leptospiral antigens and microscopically observing 
for the presence of agglutination of the antigen (12). A fourfold rise in titre between acute 
and convalescent sera is diagnostic of the disease. As the baseline titre in endemic population 
is high, only titres of >1:800 with a compatible disease is indicative of leptospirosis (1). 
Drawbacks of MAT are its complex procedure and interpretation, time-consuming and 
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hazardous nature because of the risk of exposure to the live antigen, and high degree of cross 
reactions between different serogroups and cross-reactions in other unrelated infections like 
syphilis, viral hepatitis, HIV, relapsing fever, Lyme‟s disease, legionellosis and autoimmune 
diseases.  It is insensitive particularly, in acute phase and in patients with severe disease who 
die before seroconversion (1). 
Enzyme linked immunosorbant assay (ELISA): IgM antibody detection by ELISA is the most 
widely used method for diagnosis of leptospirosis. The advantage of ELISA is that it can be 
performed easily with less infrastructure and technical expertise and is inexpensive compared 
to MAT. In addition, the ELISA can be automated, the result is objective, especially once a 
diagnostic cut-off has been decided upon, therefore having less interobserver/intraobserver 
variation. 
The ELISA for detection of antibodies in leptospirosis should be validated. The usage of well 
characterized archived specimens, consisting of those with disease and other clinically similar 
diseases allows rapid assessment of proof of concept and validation of the new assay (16).  
Assessment of specificity of a particular assay also requires testing with sera diagnosed as 
other illnesses, which present with the same clinical features. 
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                                      Aim of the study 
 
To assess the usefulness of a loop-mediated isothermal amplification (LAMP) assay and 
ELISA for the diagnosis of leptospirosis 
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                                  Objectives of the study 
 
1. To revalidate the diagnostic cut-off of ELISA used for confirming a clinical diagnosis of 
leptospirosis. 
2. To establish a LAMP assay for detection of leptospirosis. 
3. To assess the utility of LAMP assay for diagnosis of leptospirosis. 
4. To compare the utility of LAMP, PCR and ELISA for diagnosis of leptospirosis. 
5. To correlate clinical features with the diagnosis of leptospirosis. 
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                                         Review of Literature 
History 
Leptospirosis is a zoonosis which dates back to time immemorial. In ancient China, 
leptospirosis was known as an occupational hazard for the rice farmers and the Japanese 
name „akiyami‟ which means  autumn fever is still prevalent today (17). Several cases of 
leptospirosis were mentioned but the actual description of the disease or the causative agent 
was not known for many years. In 1886 a German physician Adolf Weil, Professor of 
Medicine at Heidelberg first described the disease leptospirosis. It is in his honour that the 
severe form of leptospirosis is named as Weil‟s disease. In 1907 Arthur Stimson first 
visualised the organism in silver stained preparations of liver tissue of a patient who died of 
supposed yellow fever, the causative agent of which was not known. Later, it was diagnosed 
that the patient had Weil‟s disease. At that time, it was only seen under the microscope but 
not grown in culture media (4). It was first cultured in 1915 by Inada et al in Japan, from 
blood of coal miners with infectious jaundice, who named the causative agent as Spirochaeta 
icterohaemorrhagiae (18) and Uhlenhuth and Fromme in Germany, who isolated it from 
soldiers and named it as Spirochaeta icterogenes, after inoculation of blood into guineapigs 
(19). In 1914, a saprophytic leptospira was isolated from fresh water. It was called Leptospira 
biflexa (4). The name Leptospira meaning “thin spirals” was given by Hideyo Noguchi in 
1918 (20). In 1917, rat was identified as the source for transmission of the disease to humans 
(21). Between 1920 and 1950, different serotypes with their geographic distribution, and 
hosts were identified (22). During 1960s, the detailed structure of leptospira was seen under 
the electron microscope. In 1966, Yanagawa and Faine conclusively showed that leptospira 
are similar to other bacteria in structure. They have a characteristic antigen on their cell 
surface (4).  
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Agent 
The causative agent of leptospirosis is leptospira. Leptospira belongs to the phylum 
Spirochaetes, order Spirochaetales and family Leptospiraceae (23). It is a thin spiral bacteria 
measuring 0.1µm by 6-20µm (24). The name is derived from the Greek word “leptos” 
meaning thin and Latin word “spira” meaning coil (24). They are very slender, delicate 
organisms. They have pointed ends which are bent in hooks, sometimes the ends may not 
have a hook. The straight forms of leptospira travel much slower than the hooked forms. 
Leptospira exhibit both translational and rotational motility or cork-screw motility because of 
the presence of periplasmic axial filamentous flagella (1). 
Traditionally, leptospira was classified into two species - the pathogenic leptospira which are 
pathogenic or parasitic in humans and animals known as Leptospira interrogans and the non-
pathogenic free-living saprophytic species called Leptospira biflexa. Both the species have 
many serogroups in them (25). Based on DNA hybridization analysis leptospira are now 
classified into several genomospecies (3). On the basis of the surface exposed 
liopopolysaccharide, leptospira are classified into various serogroups and each serogroup has 
numerous serovars in it. Currently there are 24 serogroups and 250 serovars (3) and 20 
genomospecies of leptospira (2). The pathogenic genomospecies which are predominantly 
responsible for causing human diseases are Leptospira interrogans, Leptospira kirschneri, 
Leptospira borgpetersenii, Leptospira noguchii, Leptospira alexanderi, Leptospira weilii, 
Leptospira santarosai (26). The genomospecies and the serogroups are not mutually 
exclusive – one serogroup may be present in more than one genomospecies (27).  
Table 3.1 shows the different genomospecies along with the serogroup and number of 
serovars included in it. 
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Table 3.1: Genomospecies and serogroups of leptospira (26,27) 
Genomospecies Serogroup  Serovar  
L. interrogans  Icterohaemorrhagiae 
Australis 
Autumnalis 
Bataviae 
Canicola 
Pomona 
Grippotyphosa 
Sejroe 
18 
9 
8 
5 
12 
8 
3 
10 
L. kirschneri  
 
Autumnalis 
Canicola 
Pomona 
Grippotyphosa  
5 
3 
3 
7 
L. borgpetersenii  Sejroe 
Javanica 
10 
10 
L. noguchii  
 
Icterohaemorrhagiae 
Australis 
 Bataviae  
5 
4 
2 
L. alexanderi  Javanica 1 
L. weilii  
 
Javanica 
Sarmin 
3 
1 
L. santarosai  Bataviae 
Pomona 
Sejroe 
5 
2 
5 
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Cell wall structure 
Leptospira has an inner membrane (IM) and an outer membrane (OM). The peptidoglycan 
cell wall is associated with the inner membrane, iron transporter (FeoAB), penicillin-binding 
proteins (PBPs) and the lipoprotein LipL31. The leptospiral outer membrane contains 
lipopolysaccharide (LPS), the transmembrane porin, outer membrane protein L1 (OmpL1) 
and the lipoproteins LipL32, LipL36 (on the inner surface of the OM), LipL41 and LigB (28) 
as shown in the Figure 3.1 below. 
 
 
 
  Figure 3.1: Cell wall structure of leptospira                                                  Reference (28) 
These outer membrane proteins like LipL32, LipL41, OMPL1 and LigB are used as antigens 
for serological tests as well as targets for different molecular assays. In a study by Haake et 
al, it shows that these targets have high specificity for Leptospira interrogans (29). Hence 
these targets are used for detection of pathogenic leptospira. 
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Epidemiology 
Global Epidemiology 
There annual incidence of leptospirosis is 5 per 100,000 population worldwide. The median 
annual incidence varies in the different continents.  
According to the second meeting on leptospirosis by World Health Organisation held in 2010  
(30) the incidence of leptospirosis is shown in table 3.2. 
Table 3.2: Global incidence of leptospirosis 
Region Incidence  
African Region 95.5 per 100,000 population 
Western Pacific 66.4 per 100,000 population 
The Americas 12.5 per 100,000 population 
South-East Asia 4.8 per 100,000 population 
Europe 0.5 per 100,000 population 
 
The annual incidence of leptospirosis varies in different parts of the world. In a study done by 
Pappas G et al the annual incidence in United Kingdom and United States of America is as 
low as 0.6 and 0.1 per million population respectively (31). In another study, done by Traxler 
et al, in USA, between 1998 to 2009 the average annual rate of hospitalisations with 
leptospirosis is 0.6 per million population (32). 
 In Asia, the incidence is high in Sri Lanka (54 per million population) and Thailand (48.9 per 
million population) (31) while it is low in Singapore (2 per million population). In India, 
although the actual incidence of leptospirosis is not known, it is considered as probably 
endemic for leptospirosis (31).  
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Leptospirosis in India 
In India, the overall annual incidence is not known. According to the data available, the 
annual incidence is highest in Andaman Islands with 500 per million population (31). In a 
multicentric study done by Indian Council of Medical Research the disease burden was found 
to be 12.7% among 3682 patients of acute febrile illness in 13 different centers (33).  The 
prevalence of leptospirosis is dependent on the geographical area, the number of patients 
recruited and the method of diagnosis.  
The varying prevalence of leptospirosis in febrile patients in different parts of the country is 
shown in table 3.3.  
Table 3.3: Indian studies on leptospirosis prevalence 
Year  Place Population  Number 
tested 
Prevalence Method of 
diagnosis 
Reference 
2002–2008 Kolkata  Fever 
patients 
404 52.97% IgM ELISA (34) 
2004–2008 Chandigarh Fever 
patients 
1391 16.67% IgM ELISA (35) 
2000–2010 Delhi  Fever 
patients 
1453 26.9% IgM ELISA (36) 
2006 Andaman 
Islands 
High risk 
population 
611 52.7% MAT (37) 
 
In Chandigarh, Sethi et al showed that the incidence of leptospirosis had increased from 
11.7% in 2004 to 20.5% in 2008.  
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Leptospirosis in Tamil Nadu and Pondicherry 
In Tamil Nadu, the prevalence of leptospirosis is variable depending upon the population 
recruited. The prevalence is very high in tribal populations (38) as shown in table 3.4. 
Table 3.4: Data on leptospirosis from Tamil Nadu and Pondicherry 
Year  Place Population  Number 
tested 
Prevalence Method of 
diagnosis 
Reference 
1995 Pondicherry Febrile 
jaundiced 
patients 
       
     _ 
12% MAT (4) 
2005-2006 Pondicherry Patients with 
fever 
110 60% MAT 
IgM ELISA 
(39) 
2007-2008 Vellore Patients with 
fever 
398 3% IgM ELISA (40) 
2008 Marakkanam 
village  
Irula tribal 
population 
72 61.1% MSAT (38) 
2008 Chennai Urban patients 
with fever 
3830 19.5% MAT 
DFM 
(41) 
2008-2010 Vellore 
district 
Patients with 
fever 
129 7.75% MSAT 
MAT 
(42) 
2011-2012 Villupuram 
district 
Urban patients 
with fever 
1502 4.32% IgM ELISA 
MSAT 
(43) 
2011- July 
2014 
Vellore Fever patients 1833 3.49% IgM ELISA Not 
published 
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Leptospirosis is a zoonosis due to an interaction of host factors, agent factors and 
environmental factors. 
 Host Factors  
There are many animals that commonly develop or spread leptospirosis as reservoirs which 
include rodents, raccoons, cattle, swine, dogs, horses, buffaloes, sheep, goats among others 
(44).  The animals once infected may remain as carriers throughout their life and shed the 
bacilli forever. The soil and vegetation are contaminated with the urine of these chronic 
carrier animals. The major route of transmission to humans is by contact with infected 
animals, soil or water where the bacteria are present (24). The risk is more in farmers, sewer 
workers, slaughterhouse workers, veterinarians and animal caretakers, fresh water fishermen, 
dairy farmers, military personnel (45). A study by Sugunan A P et al showed that barefoot 
walking and standing in water while working are risk factors associated with acquiring the 
infection (46). Earlier it was thought that leptospirosis is a disease of the poor and people of 
lower socioeconomic status. But now, the concept has changed. It can also occur among 
those involved in outdoor freshwater activities like swimming, rafting, kayaking etc. There is 
a report in Sri Lanka of 20 people who went for rafting and 17 of them developed antibodies 
to leptospira as shown by MAT or IgM ELISA  (47). Sometimes, leptospirosis is acquired in 
the course of travel. Lagi F et al reported that two Australian tourists were infected with 
leptospira after immersion in a canal in Venice in Italy (48). In a study done on 60 patients 
with leptospirosis by Guerrier P et al it was shown that leptospirosis is more severe in 
adolescents than in children (49). Another study by Spichler A et al showed that among 370 
patients, adults had higher rates of hepatic and renal derangement as shown by jaundice, 
oliguria, raised bilirubin and creatinine levels in comparison to the children. The overall case 
fatality rate was 27% for adults and 5% for children (50). 
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Agent factors  
The severity of the illness is also dependent on the infecting serovar. The common species 
causing severe disease in humans are L. interrogans, L. kirschneri, L. noguchii, L. santarosai, 
L. borgpetersenii, L. weilii, L. alexanderi, L. fainei and L. meyeri. There are some species like 
L. inadai, L. broomii and  L. licerasiae of indeterminate pathogenicity in causing disease and 
others like L. wolbachii and L. biflexa which are non - pathogenic (24). 
 
Environmental Factors  
 The risk factors associated are –  
i. Exposure to animals: Leptospirosis is a zoonosis, classically transmitted by contact with 
infected rat urine. The animals serve as renal carriers of leptospira (51). In a study in 
Chile, it was shown that presence of dogs and rodents were related more with the water 
samples of puddles which had leptospira as detected by PCR (52).  
ii. Poor sanitation and inadequate waste disposal: The disease is more common in urban 
slums. In a study, it showed that slum residents had a higher risk of greater than 3% per 
year of acquiring leptospira infection (53). Garbage is a breeding place for rodents. It is 
associated with construction and land – use in the megacities, during fairs and festivals 
when there is more movement of people and less maintenance of hygiene (54). In the 
cities the drains get blocked and water overflows onto the streets resulting in people 
coming in contact with wet mud (55). 
iii. Temperature: Leptospirosis occurs during the hot months of the year as the organism can 
survive for long periods in the hot months (54). 
iv. Rainfall and flooding: Leptospirosis occurs more during the monsoon and is more 
common in low-lying areas. This is probably due to contamination occurring during 
floods (54). The major outbreaks of leptospirosis in India have occurred during the rainy 
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season. Table 3.5 shows the data with the corresponding methods for detection of the 
disease. Currently no published data is available on leptospirosis outbreaks after 2006. 
Table 3.5: Outbreaks of leptospirosis in India (1999 – 2006) 
Year Place Number of 
Cases 
Positives  Methods of 
Diagnosis 
Reference 
1999 (October- 
November) 
Orissa 142 28.17% 
19.71% 
IgM ELISA 
MAT 
(56) 
2000 July Mumbai  102 36.27% IgM ELISA 
DGM 
(57) 
2000 (July- September) Mumbai 53 33.9% IgM ELISA (58) 
2002 (October- 
November) 
Andaman 
Islands 
156 33.33% MAT (46) 
2002 (July –October) Kerala 340 282 
255 
MAT 
IgM ELISA 
(59) 
2003 Chennai  69 35% MAT 
PCR 
(60) 
2003 Raichur  6 villages 1516 IgM ELISA (61) 
2005 (July- September) Mumbai  942 34.3% Leptotek, 
Dridot, 
Leptocheck 
(62) 
2005 (August- October) Chittoor 86 56.97% DGM 
IgM ELISA 
(63) 
2006 Gujarat  1258 55.8% MAT, PCR 
IgM ELISA 
(64) 
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Figure 3.2: Leptospirosis epidemiology in India 
 
Reported cases of Leptospirosis 
 Prevalence studies 
   Outbreaks reported 
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Pathogenesis 
Leptospires enter the body through cuts, abrasions or scratches on the skin, mucous 
membranes and conjunctivae and rarely through inhalation of droplets. Upon entry, 
hematogenous dissemination, penetration of tissue barriers and transendothelial migration of 
the organisms help in the spread. Severe vascular injury causes pulmonary haemorrhage, 
tubular epithelial cell necrosis and ischaemia in renal cortex and liver damage. The virulence 
factors are toxin production, adhesins, and other surface proteins (24).  
 
Clinical features 
Leptospirosis has a wide spectrum of disease ranging from subclinical illness to severe 
disease. A self – limiting illness is seen in 90% cases. The mean incubation period is 10 days 
(range of 5 – 14 days). In classical leptospirosis, there are two phases of the disease – a 
septicaemic phase followed by an immune phase (24).  
The illness begins with a high fever of 38 – 400 C associated with headache, chill, rigor and 
myalgia. In the septicaemic phase, the other symptoms are abdominal pain, anorexia, nausea, 
vomiting, diarrhoea, cough and pharyngitis. Conjunctival suffusion and tenderness in calf 
muscles and lumbar areas are characteristic physical findings though these are present in a 
minority of cases. A maculopapular rash occurs rarely. On examination, lymphadenopathy, 
splenomegaly and hepatomegaly may be present. This acute phase lasts for 5 – 7 days (24). 
As the symptoms are non-specific, leptospirosis should be differentiated from malaria, 
dengue and rickettsial fever (65). 
In the immune phase the organism is cleared from blood. It can be detected in tissue and 
urine. In addition to the acute phase symptoms, in the immune phase,  the characteristic 
symptoms are jaundice, renal failure, cardiac arrhythmias, pulmonary symptoms, aseptic 
meningitis, conjunctival suffusion with or without haemorrhage and photophobia (24).  
31 
 
In a study done in India, the common clinical features in leptospirosis patients are fever 
(100%), myalgia (78.4%), headache (41.2%), oliguria (29.4%), respiratory distress (25.5%) 
and bleeding manifestations (9.8%). Icterus was found in 74.5% of patients and tachypnoea 
in 52.9% (66). 
 In the severe form of the disease, which occurs in 10% patients, the illness is complicated 
with combination of renal failure, liver failure and pneumonitis with haemorrhagic diathesis 
and aseptic meningitis. The severe form of leptospirosis or Weil‟s disease is a triad affecting 
liver, kidney and lung (Figure 3.3). The mortality ranges from 5 - 40% in the severe disease 
(24). 
 
Figure 3.3: Weil’s disease triad 
Co – infection 
Leptospira infection can occur in patients with other diseases. Concurrent infection of 
leptospirosis can occur with typhoid fever, brucellosis and rickettsial infection (67). 
Simultaneous detection of antibodies to leptospira and scrub typhus is quite common. In 
2003, a case of concurrent infection of scrub typhus and leptospira was reported in a patient 
with acalculous cholecystitis  (68). In 2012, another case of co-infection with scrub typhus 
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and leptospira was reported by Wei et al. However, both the cases responded well to 
management (69). A similar case was reported from the Himalayan region in India in 2012 
(70). In 2013, a study by Sonthayanon et al showed that out of the 82 cases who had 
serological evidence of dual infection of leptospira and scrub typhus, 5(6%) had molecular 
evidence of combined infection (71). Among the other diseases, two cases of malaria and 
leptospirosis were reported in 2011 (72). Malaria, leptospirosis and dengue occurred together 
in 0.1% while dengue and leptospirosis were seen in 1.6% patients with acute febrile illness 
in Jamaica in 2013 (73). Dengue and leptospira combined infection was also seen in Puerto 
Rico in 2010 (74). In 2012, four cases were reported with co-infection of leptospira and 
Burkholderia pseudomallei in Malayasia (75). 
Leptospira can be isolated from blood, urine and CSF (Figure 3.4). 
 
                                                  Days of illness                                      Adapted from (1) 
Figure 3.4: Samples used for diagnosis of leptospirosis 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Detection of leptospira in different samples 
IgM
Blood 
Urine 
CSF 
Septicaemic phase Immune phase 
33 
 
Laboratory Diagnosis 
The common methods used for diagnosis of leptospirosis are given below (Figure 3.5) 
 
Figure 3.5: Flowchart of commonly used methods for diagnosis of leptospirosis  
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Microscopy 
Dark field/ phase contrast microscope  
 As leptospira is a thin, delicate organism, it cannot be seen under the light microscope. It is 
visible only under dark field microscope or phase contrast microscope. It has a characteristic 
cork – screw motility due to a combination of translational and rotational movements (23). 
The limit of detection of dark field microscopy is 10
4
 leptospires/ml (1). A buffy coat method 
has a lower detection limit of 10
3 
leptospires/ml (76). A better method is microscopic 
examination of double centrifuged anticoagulated blood. It can be used for direct microscopy 
in blood, urine, dialysate fluid and for confirmation of culture. Microscopy of blood is useful 
only during the first few days of the acute illness during the phase of leptospiremia. However, 
it can sometimes be detected as early as the fourth day before the appearance of symptoms. 
Dark field microscopy is a rapid method for diagnosis of leptospirosis (1). Microscopy of 
urine should be performed immediately as the acidic urine causes lysis of the organism. The 
organism is shed intermittently in urine giving false negative results (77). False positives can 
occur with artefacts like RBCs, fibrils and protein threads (1). 
In a study by Sharma et al, 297 cases of clinically suspected leptospirosis were recruited and 
tested by dark field microscopy and IgM ELISA for antibody detection. The sensitivity and 
specificity of dark field microscopy was found to be 60% and 61% respectively (78). In 
another study, it was found that dark field microscopy has a low sensitivity  (40.2%) and 
specificity (61.5%) compared to culture (7). 
Chandrasekaran S et al found that dark field microscopy had a sensitivity of 93.3% in 
suspected cases of leptospirosis. However, the performance of dark field microscopy 
deteriorates in samples collected after the first week of illness though it  performs very well 
in the first week of fever (79).  
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Staining  
As the organism is slender and delicate, it cannot be visualized with Gram stain and special 
staining is required. Immunofluorescence, immunohistochemistry and immunoperoxidase 
staining are widely used for diagnosis of leptospira in veterinary specimen (80).  
Different histopathological stains like Warthin-Starry, Faine, or Dieterle methods are used for 
detection of leptospira in tissue specimen. Warthin-Starry stain and modified Fontana‟s stain 
which are modifications of silver staining are most widely used. In silver staining, they look 
as brown  or black spiral organisms in yellow tissue background and should be differentiated 
from treponema and borrelia (1). The differences between the three are shown in table 3.6. 
Other structures like erythrocytes, other bacteria and yeast stain dark, but the characteristic 
shape and hooked ends of the leptospira differentiate it from other cells (81). 
Table 3.6: Differentiating features between leptospira, treponema and borrelia in silver 
staining 
Characteristics Treponema Leptospira  Borrelia  
Length  5-15µ 6-20 µ 10-30 µ 
Width  0.2 µ 0.1-0.3 µ 0.3-0.7 µ 
Primary coil Closely wound Very closely wound Loosely wound 
Winding  Regular  Regular  Irregular  
Schematic diagram  
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Culture  
Culture is the gold standard for diagnosis of leptospirosis. Leptospira is an obligate aerobe 
which requires vitamin B1, B12 and long chain fatty acids for its growth. It is incubated at 28 
– 300C and kept upto 13 weeks before declaring it as negative with regular subculture at 10 – 
14 days (1). The different culture media used are given below in table 3.7. 
Table 3.7: Culture media used for leptospira 
Media  Type  Content  Comments  
EMJH media 
 
Enriched 
 Liquid  
Albumin, polysorbate80,Na2HPO4, 
NaH2PO4, NaCl, NH4Cl, thiamine 
Most widely used 
 
Fletcher‟s media Enriched 
Semisolid  
Peptone, beef extract, NaCl, agar, 
5-Fluorouracil 
Growth seen as 
Dinger‟s ring 
Korthoff‟s media 
 
Enriched  
Liquid  
Sodium citrate, Na2HPO4, 
NaH2PO4, NaCl, NH4Cl , peptone, 
vitamin 
 
Noguchi media 
 
Enriched 
Semisolid  
Serum, agar, minerals  
 
The most widely used media for culture of leptospira is Ellinghausen-McCullough-Johnson-
Harris (EMJH) media containing oleic acid and albumin. Blood is inoculated at bedside in the 
media for isolation of leptospira in the first week of illness. The other samples in first week 
are CSF and dialysate fluid. Multiple blood cultures are required for better yield. In the 
second week of the illness, urine is a better sample for isolation of leptospira though there is 
intermittent shedding of the organism. However, the urine should be processed immediately 
as leptospira is sensitive to acidic environment and antibodies present in urine may lyse the 
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fragile organism (1). The yield of leptospira is highest (81.3%) in whole blood as compared 
to surface plasma, deposit from spun plasma and clotted blood (82). In semisolid media the 
growth of leptospira is seen as a ring below the surface in the media. This is known as 
Dinger‟s ring or disk and it goes on increasing with further incubation. The growth is related 
to oxygen tension in the media (1). The advantage with culture is that it is 100% specific. The 
disadvantage is that leptospira is difficult to culture and has to be incubated for long period 
which leads to contamination of the culture media. Serum rich media are required for culture. 
It has a low sensitivity of 10.5%. Contaminated cultures may be passed through 0.2mm or 
0.45mm filter for purification before subculture into fresh medium. The cultured isolates are 
confirmed by serological methods or molecular methods (1). 
Antigen detection methods 
Antigen is detected in blood and urine. Several methods like radioimmunoassay (RIA),  
ELISA, countercurrent immunoelectrophoresis and staphylococcal coagglutination have been 
tried for antigen detection in blood and urine. RIA has a limit of detection of 10
4
 to 10
5
 
leptospires/ml whereas ELISA needs the presence 10
5
 leptospires/ml. An immunomagnetic 
antigen capture combined with fluoroimmunoassay has shown a detection limit of 10
2
 
leptospires/ml (1). In a study done by Saengjaruk P et al, the antigen detection in urine by 
monoclonal antigen based ELISA in urine was 75% and 100% on the first day and the 
fourteenth day of illness (83). In another study done by Nizamuddin M et al, 19.2% patients 
had leptospira antigen detectable in blood by ELISA (84).  
Animal inoculation methods 
Different animals like guinea pigs, hamsters, gerbils, young rabbits, swiss albino mice and 1 
to 3 days old chicks are inoculated intraperitoneally for isolation of leptospira. A drop of 
peritoneal fluid can be examined with dark-field microscopy for active leptospires from the 
3rd to the 7th day (4).  
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Serology  
Microscopic agglutination test 
MAT (microscopic agglutination test) is the reference method for serological diagnosis of 
leptospirosis. The presence of leptospiral antibody in the patient‟s serum is determined by 
incubating it with serogroup specific live leptospiral antigens and microscopically observing 
for the presence of agglutination of the antigen (12). After incubating for about 2 hours at 
30°C, the results are taken under a dark field microscope. The last dilution in which ≥ 50% of 
the leptospires are agglutinated is the titre. Seroconversion or four fold titre rise in paired sera 
is consistent with the diagnosis of leptospirosis. The significance of a titre in a single sample 
depends on the frequency of residual titre due to past infections and cross-reacting other 
diseases in the population (85). The drawbacks of MAT are - 
i. It is complex, time-consuming procedure and interpretation is difficult. 
ii. Hazardous nature because of the risk of exposure to the live antigen. 
iii. Difficulty in maintaining the serovars necessitates continuous weekly subculturing of the 
strains. 
iv. It requires periodic verification of the strains.  
v. It gives false negative reactions in delayed seroconversion, which sometimes occurs by 
30 days after infection. 
vi. High degree of cross reactions between different serogroups and cross-reactions in other 
unrelated infections like syphilis, viral hepatitis, HIV, relapsing fever, Lyme‟s disease, 
legionellosis and autoimmune diseases are due to the persistence of IgM antibodies for 
long time (24).   
vii. It is insensitive particularly, in acute phase and patients with severe disease who die 
before seroconversion (1).  
39 
 
ELISA 
Enzyme linked immunosorbant assay (ELISA): IgM ELISA, IgM capture ELISA and IgM 
dot ELISA-dipstick to detect IgM antibodies against leptospires have been developed for 
diagnosis. Different antigens have been used for detection of antibody against leptospira as 
shown in table 3.8 below. 
Table 3.8: Antigens used for detection of IgM antibodies to leptospira by ELISA  
Antigen  Compared 
to   
sensitivity  Specificity  Reference  
Recombinant Lsa63 produced in E.coli  
 
 
 
 
   MAT 
 
93.8% 81.29 % (86) 
Leptospiral Ig-like protein B (LigB) 96.9% 91.08% (87) 
C-terminal coding sequence of ligA 
(ligA-C) cloned produced in Escherichia 
coli 
92.1% 97.7% (88) 
Purified recombinant antigens rLipL32,  
rLipL41 and rLigA-Rep (leptospiral  
immunoglobulin -like A repeat region) 
90%   - (89) 
LipL32 96.4% 90.4% (90) 
Recombinant LipL32 antigen 100% 85.1% (91) 
Leptospira fainei (whole cell extract) 94% 99% (92) 
rLipL32/1-LipL21-OmpL1/2-IgM-
ELISA 
97.5%  - (93) 
 
An IgM antibody capture enzyme-linked immunoassay using the M20 strain of Leptospira 
interrogans serovar Copenhageni has a sensitivity and specificity of 92.3% and 56.0% 
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respectively (94). The commercially available ELISA mostly uses the recombinant leptospira 
antigen for detection of antibodies. 
IgM detection is more sensitive than MAT in early disease. The advantage of ELISA is that it 
can be performed easily with less infrastructure and technical expertise and is inexpensive 
compared to MAT. In addition, the ELISA can be automated, the result is objective, specially 
once a diagnostic cut-off has been decided upon, therefore having less 
interobserver/intraobserver variation. Since many other diseases have similar clinical 
manifestations the ELISA should be validated. The usage of well characterized archived 
specimens, consisting of those with disease and other clinically similar diseases allows rapid 
assessment of proof of concept and validation of the new assay (16).  
IgM ELISA is the most widely used method for diagnosis of leptospirosis. Hence, the ELISA 
should be validated and the cut–off should be determined in the different regions based on the 
local prevalence of the disease in that particular region. 
Rapid tests 
Rapid tests like immunochromatographic test, flow-through assay and latex agglutination 
tests have variable sensitivity and specificity. A simple latex agglutination assay 
„Leptorapide‟ ((Linnodee Ltd, Northern Ireland) was evaluated and had a sensitivity and 
specificity values of 97·1% and 94·0%, respectively, when compared to the microscopic 
agglutination test. The agglutination is graded in a score of 5 (95). In another study by Goris 
et al three different rapid tests, LeptoTek Dri Dot (bioMe´rieux B.V. Boxtel, the 
Netherlands), LeptoTek Lateral Flow (Organon Teknika B.V. Boxtel, the Netherlands) and 
Leptocheck-WB (Zephyr Biomedicals, Verna Goa, India) were evaluated. Lepto-Tek Lateral 
Flow and Leptocheck-WB are lateral flow immunochromatographic tests, while LeptoTek 
Dri Dot is a latex agglutination assay. The overall sensitivity and specificity for the LeptoTek 
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Dri Dot was 75% and 96%, for the LeptoTek Lateral Flow 78% and 95%, and for the 
Leptocheck-WB 78% and 98% respectively (96). A novel vertical flow 
immunochromatography rapid diagnostic test showed a sensitivity of 89.8% and a specificity 
of 93.7% (97). In a study by Senthilkumar et al using recombinant LipL41 antigen for 
detection of antibody against leptospira, two rapid tests – latex agglutination test and flow-
through assay were evaluated. The latex agglutination test had a sensitivity and specificity of 
98.7% and 90.45% and the flow-through assay had sensitivity and specificity of 89.09% and 
77.70% respectively compared to MAT (98).  
The advantages of these rapid tests are that they do not require any training, are easy to 
perform and can be performed in the resource – limited and field settings. They give results 
within minutes to four hours (99). 
The disadvantage is that they give false positive results with HIV, Hantavirus, Toxoplasma, 
Lyme disease, malaria, meningococcal meningitis and hepatitis A infection (1). 
 
Other serological tests 
A macroscopic slide agglutination test using 12 serovars was used for antibody detection but 
it had false negative results in the endemic regions (1). A modified macroscopic slide 
agglutination test with serovar patoc as the antigen has been used for the detection of 
antibodies to leptospira. Brandao et al found that the sensitivity and specificity of 
macroscopic slide agglutination test was similar to IgM ELISA for detection of antibodies in 
leptospira infection (100).  
Other tests like indirect haemagglutination test using sensitised red blood cells developed by 
CDC, microcapsule agglutination test using a synthetic polymer in place of red blood cells, 
counter immunoelectrophoresis and thin-layer immunoassay have been described and 
evaluated but are not widely used for diagnosis of leptospirosis (1). 
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Molecular methods 
PCR 
Polymerase chain reaction (PCR) is one of the most widely used methods for diagnosis of 
leptospirosis in acute febrile illness. The genes commonly used for detection of leptospiral 
DNA detection by PCR are LipL32 coding for outer membrane lipoprotein LipL32 (8), rrs 
for 16S rRNA (9) and secY coding for pre-protein translocase SecY protein (10). PCR has 
been done for different targets by different groups which are given in the table 3.9 below with 
their sensitivity and specificity. 
Table 3.9: PCR performance for diagnosis of leptospirosis 
Year  Sample  Target  Number 
tested 
Compared 
to  
Sensitivity  Specificity  Reference  
2006 Blood  16S rRNA 60 MAT 
Culture 
62-72.7% 100% (101) 
2009 Blood  secY gene 133 Culture 89-100% 93-100% (10) 
2010 Blood  rrs gene 
LipL32 
266 Culture 
MAT 
56% 
43% 
90% 
93% 
(8) 
2011 Blood  rrs gene 418 Culture 94.8%         - (9) 
2012 Blood  16S rRNA 1652 Culture 
MAT 
52.7% 97.2% (102) 
2012 Blood 
urine 
16S rRNA 261 MAT 
IgM ELISA 
94.4% 100% (103) 
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These genes have also been used in MLST (multilocus sequence typing) for typing leptospira 
(104). Recently, amplification of the rfb gene which codes for LPS in leptospira has been 
found to be partially successful for determination of serovar by Silva et al (105). This is in 
agreement with the opinion stated by Patarakul K regarding the lack of similarity between 
leptospiral serovars and sequence information (106). The currently available PCRs detect 
leptospira DNA effectively as they are designed based on the conserved regions but are 
unable to further classify them into serovars. The advantages of PCR are that it is rapid and it 
can detect the organism even during the first week of illness before the appearance of 
antibodies and hence aids in early initiation of treatment. The limitations of PCR are that it is 
costly as it requires technical expertise and expensive infrastructure and is also labor – 
intensive. Further, it cannot identify the infecting serovar. This can be overcome by 
restriction endonuclease digestion of PCR end-products, direct sequencing of amplicons, and 
single strand confirmation analysis.  
 
LAMP 
LAMP (loop-mediated isothermal amplification) is an alternative method of DNA 
amplification with high specificity, efficiency and occurs under isothermal conditions. It 
employs a DNA polymerase and a set of four specially designed primers that recognise six 
DNA sequences on the target DNA (11). The final products of LAMP are stem-loop DNAs 
with several inverted repeats of the target and cauliflower-like structures with multiple loops 
formed by annealing between alternately inverted repeats of the target in the same strand. 
These enable their simple, easy, selective detection by electrophoresis (12). The reaction 
results in the accumulation of 10
9 
copies of target. The LAMP assay simply requires a 
laboratory water bath or heating block to maintain a constant temperature of 60–65°C, 
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making it particularly suitable for resource poor settings (6). Detection of products is done by 
agarose gel electrophoresis, real-time monitoring in an inexpensive turbidometer or in the 
form of a colour change when SYBR Green I, a fluorescent dsDNA intercalating dye is used 
which detects turbidity or a pellet.  Moreover, the LAMP assay is not affected by polymerase 
inhibitors (12). 
The advantages of LAMP assay are – 
1. LAMP amplifies DNA with high efficiency under isothermal condition. It does not require a 
thermal cycler like PCR and can be done in a water-bath/ heating block at 65
0
C.  
2. It is a sensitive test with detection limit of a few copies (11).  
3. The end products are a mixture of stem- loop DNAs which can be easily detected by naked 
eye by turbidity, fluorescent dye or colorimetry like antigen- antibody reactions (12). 
4. LAMP is highly specific for target sequence due to recognition of target by six independent 
sequences in the initial stage and four independent sequences in the later stage.  
5. LAMP is simple and easy to perform and less expensive as it requires only primers, a DNA 
polymerase and a water bath.  
6. By combination with reverse transcription, LAMP can amplify RNA sequences with high 
efficiency. 
7. LAMP is not affected by polymerase inhibitors  and haem (11). 
Lin et al in 2009 developed a LAMP assay targeting the LipL41 gene and reported the lower 
detection limit of 100 genome equivalents similar to PCR in mouse kidney sample. The assay 
was easier and inexpensive compared to PCR (13). 
Sonthayanon et al developed another LAMP assay targeting the rrs gene and found the 
analytical sensitivity of 10 genome equivalents.  They also performed clinical evaluation of 
the rrs LAMP and the LipL41 LAMP in blood samples from cases positive by culture and/or 
MAT, and in controls with other febrile illness. The sensitivity and specificity for rrs LAMP 
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was 43.6% and 83.5% respectively, while for the LipL41 LAMP the sensitivity and 
specificity was 37.6% and 90.2% respectively. This difference was not found to be 
statistically significant. Among patients who were positive for blood culture, the sensitivity 
for rrs and LipL41 LAMP assay were higher at 84.6% and 74.4% respectively. The poor 
sensitivities of both the LAMP assays found in the study were attributed to common use of 
over-the-counter antibiotics or presence of low number of organisms in blood below the 
detection limit of either assay. The authors suggested that additional clinical evaluation was 
necessary before LAMP could be used for diagnosis (6).  
Since leptospiral DNA have been detected from urine both in early and late disease by PCR 
rather than in blood, Koizumi et al developed an rrs LAMP assay which can be used in 
heated urine samples.  The lower detection limit of the assay was 2 and 10 genome 
equivalents per reaction under heat-denaturing and non-denaturing conditions. The 
performance of the assay was evaluated in urine of field mice. The assay was positive in 11 
of 12 culture positive boiled urine and in 10 of 11culture positive urine pellet samples. The 
LAMP assay was also positive in two culture negative samples, suggesting a higher 
sensitivity than culture. As shedding of the leptospires occur intermittently, the authors 
suggested repeated testing using nucleic acid amplification (14).  
In another study by Suwancharoen D et al, the detection limit was upto 10 to 100 copies 
using 16S rDNA as the target. In this study DNA from 22 pathogenic and 2 non-pathogenic 
leptospira and some other bacteria like Enterococcus faecalis, Staphylococcus aureus, 
Proteus mirabilis were used. The LAMP assay was compared to standard PCR and it was 
found that LAMP assay was 10-100 times more sensitive than PCR. The LAMP assay 
detected all the pathogenic leptospira but none of the non-pathogenic leptospira or other 
bacteria (15). 
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The summary of all these LAMP studies with their detection limit, sensitivity and specificity 
are given below in table 3.10.  
Table 3.10: Summary of LAMP assay findings of the four research groups   
Year  Sample  Target  Detection 
limit 
Compared 
with 
Comments  Reference 
2009 Monkey 
kidney 
sample 
LipL41 
gene 
100 genome 
equivalents 
Real- 
time PCR 
Detection limit same as 
PCR 
(13) 
2011 Blood  rrs gene 
 
10 genome 
equivalents 
Culture Sensitivity 43.6% and 
Specificity 83.5%  
(6) 
LipL41 
gene 
Sensitivity 37.6% and 
Specificity 90.2%  
2012 Urine of 
rats 
rrs gene 2 to 10 
genome 
equivalents 
Culture, 
FlaB 
nested 
PCR 
Specificity 66.7% and 
Sensitivity is 11 of 12 in 
boiled urine, 10 of 11 in 
urine pellets  
(14) 
2012 DNA of 
22 
pathogenic 
and 2 non- 
pathogenic 
leptospira  
16S rDNA 10 to 100 
copies 
PCR Sensitivity - 10-100 
times more sensitive than 
PCR 
Specificity – 100% with 
pathogenic leptospira 
(15) 
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Case definition of leptospirosis 
The gold standard for diagnosis of leptospirosis being culture; it cannot be done on all 
samples. So a composite criteria is needed to make sure that no case of leptospirosis is 
missed. Such composite criteria are given by WHO, CDC, Faine‟s and modified Faine‟s 
criteria. 
World Health Organisation – Definition (44) 
According to World Health Organisation - The clinical features consist of an acute febrile 
illness with headache, myalgia (particularly calf muscle) and prostration associated with any 
of the following symptoms/signs:  
Conjunctival suffusion  
Anuria or oliguria  
Jaundice  
Cough, haemoptysis and breathlessness  
Haemorrhage from the intestine and lung  
Meningeal irritation  
Cardiac arrhythmia or failure  
Skin rash 
Other common symptoms include nausea, vomiting, abdominal pain, diarrhoea, arthralgia 
.  
Laboratory criteria  
Presumptive diagnosis:  
A positive result of a rapid screening test such as IgM ELISA, latex agglutination test, lateral 
flow, dipstick etc.  
Confirmatory diagnosis:  
i. Isolation from blood or other clinical materials through culture of pathogenic leptospira   
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ii. A positive PCR result using a validated method (primarily for blood and serum in the 
early stages of infection).  
iii. Fourfold or greater rise in titre or seroconversion in microscopic agglutination test (MAT) 
on paired samples obtained at least 2 weeks apart. A battery of Leptospira reference 
strains representative of local strains should be used as antigens in MAT.  
 
Case classification  
Suspected: A case that is compatible with the clinical description and a presumptive 
laboratory diagnosis.  
Confirmed: A suspect case with a confirmatory laboratory diagnosis.  
 
Centre for Disease Control and Prevention – Definition (107) 
 
Clinical features are 
i. History of fever within the last two weeks and  
ii. At least two of the following features - myalgia, headache, jaundice, conjunctival 
suffusion and maculopapular rash.  
iii. Or at least one of the following clinical findings - septic meningitis, gastro intestinal 
symptoms (abdominal pain, nausea, vomiting, diarrhoea), pulmonary symptoms 
(cough, breathlessness, haemoptysis), cardiac arrhythmias, renal insufficiency (anuria, 
oliguria), haemorrhage (intestinal, pulmonary, haematuria, hematemesis), jaundice 
with acute renal failure. 
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Laboratory Criteria for Diagnosis 
Supportive: Any of the following 
i. Microscopic agglutination test (MAT)  has a titre of ≥ 200 but < 800  in one or more 
serum specimens. 
ii. Demonstration of anti leptospira antibodies in a clinical specimen by indirect 
immunofluorescence. 
iii. Demonstration of leptospira in a clinical specimen by darkfield microscopy 
iv. Detection of IgM antibodies against leptospira in an acute phase serum specimen. 
Confirmed: Any of the following 
i. Isolation of leptospira in culture from a clinical specimen. 
ii. Fourfold or greater rise in titre between acute and convalescent serum.  
iii. Demonstration of leptospira in tissue by direct immunofluorescence. 
iv. Microscopic agglutination test (MAT) shows a titre of ≥ 800 in one or more serum 
specimens. 
v. Detection of pathogenic leptospira DNA (by PCR) from a clinical specimen. 
 
Epidemiologic Linkage: This includes occupational, recreational or vocational exposure to 
animals or environments contaminated with animal urine like involvement in an exposure 
event (adventure race or flood). 
 
Case Classification 
Probable: A clinically compatible case with at least one of the following: 
i. Involvement in an exposure event (adventure race, triathlon, flooding) with known 
associated cases. 
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ii. Presumptive laboratory findings, but without confirmatory laboratory evidence 
of leptospira infection. 
Confirmed: A case with confirmatory laboratory results, as listed above. 
 
These case definitions are not always practically feasible as culture and PCR both have low 
sensitivity and it is very difficult to get a paired serum sample from a patient with acute 
febrile illness like leptospirosis. Moreover, even if the paired serum is obtained, rise in titre is 
not demonstrable as the patient takes antimicrobial drugs in the course of illness.  
Faine had developed a criteria for diagnosis of leptospirosis based on clinical, 
epidemiological and laboratory features (table 3.11). This criteria was modified by 
Shivakumar et al in Chennai to make it suitable for use in India (108) as given in table 3.12. 
The reason for modification is that rainfall should be taken into account as most outbreaks of 
leptospirosis occur during monsoon. Though microscopic agglutination test is the serological 
reference standard but it is complicated and difficult to perform. Hence, ELISA and slide 
agglutination test (SAT) which are simple and easy to perform have also been included in the 
criteria (109).  
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Table 3.11: Faine’s criteria for diagnosis of leptospirosis (109) 
Part A : Clinical data Score 
Headache 2 
Fever  2 
Temperature >39
0
C 2 
Conjunctival suffusion (bilateral) 4 
Meningism  4 
Muscle pain (especially calf muscle) 4 
Conjunctival suffusion + meningism + muscle pain 10 
Jaundice 1 
Albuminuria or nitrogen retention 2 
Part B: Epidemiological factors 
Contact with animals or contact with known contaminated water 10 
Part C: Laboratory findings 
Isolation of leptospira in culture – diagnosis certain  
Positive serology MAT  
Leptospirosis endemic single positive low titre 2 
Leptospirosis endemic single positive high titre 10 
Leptospirosis non-endemic single positive low titre 5 
Leptospirosis non-endemic single positive high titre 15 
Rising titre in paired sera 25 
Only one serological test should be scored 
Diagnosis of leptospirosis is Part A+ B ≥ 26 or Part A+ B+ C ≥ 25 
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Table 3.12: Modified Faine’s criteria for diagnosis of leptospirosis (109) 
Part A : Clinical data Score 
Headache 2 
Fever  2 
Temperature >39
0
C 2 
Conjunctival suffusion (bilateral) 4 
Meningism  4 
Muscle pain (especially calf muscle) 4 
Conjunctival suffusion + meningism + muscle pain 10 
Jaundice 1 
Albuminuria or nitrogen retention 2 
Part B: Epidemiological factors 
Rainfall 5 
Contact with contaminated environment 4 
Animal contact 1 
Part C: Laboratory findings 
Isolation of leptospira in culture – diagnosis certain  
IgM ELISA positive 15 
SAT positive 15 
MAT single high titre 15 
MAT rising titre in paired sera 25 
Only one serological test should be scored 
Diagnosis of leptospirosis is Part A+ B ≥ 26 or Part A+ B+ C ≥ 25 
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Treatment 
Leptospirosis is treated with supportive measures and antibiotics.  The different antimicrobial 
agents that can be used for treatment of leptospirosis are penicillin, doxycycline, cefotaxime, 
ceftriaxone and azithromycin (110). Severe disease is treated with penicillin and ceftriaxone 
while mild disease is treated with doxycycline. 
Table 3.13: Drugs used for the treatment of leptospirosis (24) 
Severity of illness Antibiotic  Dosage 
 
Severe illness 
Penicillin G 1.5MU IV 6 hourly 
Ceftriaxone 1gm IV once daily 
Ampicillin 0.5 – 1gm IV 6 hourly 
Mild illness Doxycycline  100mg twice daily 
Ampicillin  500 – 750mg 6 hourly 
 
Other antibiotics which can be used for treatment of leptospirosis are azithromycin and 
amoxicillin. In a study by Phimda et al, the efficacy of azithromycin and doxycycline were 
similar for treatment of leptospirosis. However, azithromycin is more expensive than 
doxycycline, though the former has lesser adverse effects compared to doxycycline (111). 
Ghouse et al demonstrated that 72% of the patients having leptospira infection responded 
well to treatment with azithromycin and had complete cure (112). In some conditions, 
fluoroquinolones like ciprofloxacin has also been used for treatment of leptospirosis (113).  
The complications of leptospirosis like renal failure require other measures like 
haemodialysis (24).  
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Prevention  
The prevention of leptospirosis involves the following –  
1. Prevention of exposure: This includes wearing of shoes, gloves etc. while handling 
animals, swimming in safe water to prevent occupational and recreational exposure to 
leptospira (24). 
2. Identification and controlling the source: Rain water should not be allowed to accumulate 
and prevention of contamination of water with urine of animals. 
3. Rodent control: Rodent control is a definite approach for control of leptospirosis. 
4. Control of disease in animals: The disease can be controlled in cattle by annual 
vaccination with killed vaccines.  
5. Chemoprophylaxis: Doxycycline 200 mg in weekly dose is used for chemoprophylaxis in 
military personnel and people going to the jungle (30).  
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                                   Materials and Methods 
 
This study was approved by Institutional Review Board (IRB Min no 8109 dated 5.12.2012) 
Patient recruitment 
Adult patients, having fever of duration ≤ 15 days, whose sera were sent for leptopsirosis 
serology, were recruited based on the inclusion and exclusion criteria given below. 
All the patients were recruited after obtaining an informed consent (Appendix I). 
A clinical proforma was filled up as given in Appendix II at the time of sample collection.  
Inclusion criteria:  
Patients with the following were considered as suspected cases of leptospirosis 
1. Individuals admitted with acute undifferentiated fever (≥100º F) of duration ≤ 15 days   
2. Adult patients ( ≥ 18 years) 
3. Malaria smear negative 
4. Blood culture negative  
5. Eschar negative 
 
Exclusion criteria:  
1. Individuals  who had malaria, sepsis or enteric fever  
2. Individuals who had fever with localizing signs 
3. Duration of fever ≥ 16days  
4. Individuals with fever and eschar 
5. Outpatients  
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 The study included two parts – 
I. Validation of IgM ELISA for leptospirosis and scrub typhus 
II. Evaluation of three assays for diagnosis of leptospirosis 
 
Samples: 
I. For Validation of IgM ELISA 
A. Samples used to estimate the cut – off in normal population 
Adults who were accepted as voluntary blood donors fulfilling the following criteria -  
1. Adults ≥ 18years of age 
2. Body weight ≥ 45 Kg 
3. No acute illness in the past 30 days 
4. Negative for HIV, Hepatitis B, Hepatitis C, malaria and syphilis 
5. No history of tuberculosis in last 1 year 
 
Four ml of blood from healthy blood donors was collected in EDTA tubes (BD Vacutainer, 
Franklin Lakes, NJ, USA).  
This was used for obtaining plasma. 
Four ml of blood was collected from 20 of the healthy donors in Serum tube with clot 
activator (BD Vacutainer, Franklin Lakes, NJ, USA). 
This was used for obtaining serum. 
B. For Validation of cut-off of ELISA determined 
Serum samples were collected from proven cases of scrub typhus, sepsis, malaria, enteric 
fever and dengue. The details of these are given below in table 4.1 
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Table 4.1: Samples for validation of ELISA 
Disease Number of Sample 
Scrub typhus patients having eschar * 50 
Sepsis patients (blood culture positive) 20 
Enteric fever patients (blood culture positive) 20 
Malaria smear positive patients 17 
Dengue serology positive patients 17 
* Not used for validation of scrub typhus ELISA 
These patients had no other illness except the one mentioned above. 4 ml of blood was 
collected from the patients in Serum tube with clot activator (BD Vacutainer, Franklin Lakes, 
NJ, USA). 
These sera and plasma were tested for IgM and IgG antibodies to leptospira and IgM 
antibodies to scrub typhus by ELISA. The different tests performed are given in table 4.2 
Table 4.2: ELISA tests performed  
Test for leptospirosis Kit 
IgM ELISA PanBio, (PanBio Ltd, Brisbane, Australia) 
IgM ELISA Virion serion (Serion Immundiagnostics, Wurzburg, Germany) 
IgG ELISA Virion serion (Serion Immundiagnostics, Wurzburg, Germany) 
IgM ELISA InBios (InBios International Inc, Seattle, WA) 
Test for scrub typhus Kit  
IgM ELISA InBios (InBios International Inc, Seattle, WA) 
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II. Evaluation of assays for diagnosis of leptospirosis 
Four ml of blood was collected from the patients with suspicion of leptospirosis in Serum 
tube with clot activator (BD Vacutainer, Franklin Lakes, NJ, USA). The following tests 
(table 4.3) were performed with the serum samples of the patients with acute febrile illness: 
Table 4.3: Tests for leptospirosis 
Test for leptospirosis Timing of sample 
IgM ELISA (PanBio) Paired sera: Acute & convalescent (≥ 7 days after 
obtaining the acute sample) 
Nested PCR  Duration of illness ≤ 15 days 
LAMP assay Duration of illness ≤ 15 days 
 
Sample size: 
This was a pilot study as not much data is available on the prevalence of leptospirosis in India 
in general and this area in particular. Total 150 individuals who were suspected to be 
suffering from leptospira infection were enrolled in this study as per the inclusion and 
exclusion criteria elucidated above. 
Study period:  
December 2012 to July 2014 
Separation of serum and plasma 
Serum was separated by centrifugation at 2500 rpm for 10 minutes at 4
0
C. The serum was 
stored at -70
0
C in two aliquots. Plasma was separated by centrifugation at 2500 rpm for 10 
minutes at 4
0
C.  
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Serology 
All ELISA were performed according to the manufacturer‟s instructions. Briefly the 
procedure of each is described below -  
Leptospira IgM ELISA by PanBio (PanBio Ltd, Brisbane, Australia) 
Procedure 
1. The required number of microwells were taken out and placed into the strip holder.  
2. Six microwells were labeled and kept for negative control, reactive control, calibrator in 
triplicate and in – house control.  
3. Other wells were marked for the samples. 
4. Negative control, reactive control, calibrator in triplicate, in – house control and patient 
samples were diluted. 90μl of sample diluent was added to 10µl of serum and mixed well. 
From this 20μl of the diluted serum was added to 180μl sample diluent and mixed well to 
get a final dilution of 1: 100. 
5. Then, 100μl of diluted patient samples, controls and calibrator were put into their 
respective wells. 
6. The plate was incubated at 37ºC for 30 minutes. 
7. After incubation, the wells were washed well six times with diluted wash buffer taking 
350µl each time for each well. 
8. Then, 100μl of HRP (horse radish peroxidase) conjugated anti-human IgM was added to 
each well. 
9. The plate was again incubated at 37ºC for 30 minutes. 
10. After incubation the wells were washed well six times with diluted wash buffer taking 
350µl each time for each well. 
11. After that, 100μl of TMB (tetramethylbenzidine) was put into each well. 
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12. The plate was incubated at 20-250C for 10 minutes. 
13. Finally, 100μl of stop solution was added into each well and mixed well. 
 
 
Reading 
Within 30 minutes, the absorbance of each well was read at a wavelength of 450 nm with a 
reference filter of 600-650 nm. 
 
Calculation 
1. The average absorbance of the triplicates of the calibrator was calculated. 
2. Cut-off Value = Average of Calibrator x Calibration factor 
3. Index value  = Sample Absorbance/Cut-off Value 
4. Result in PanBio Units was calculated by multiplying the index value by 10. 
 
Interpretation 
The negative control, positive control and calibrator control readings were taken and 
calculations were done. 
For each sample the result was calculated in PanBio units. 
The results for all samples in PanBio units were entered in the excel sheet. 
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Leptospira IgM ELISA (Virion serion, Serion Immundiagnostics, Wurzburg, Germany) 
Procedure 
1. The microwells were taken out and placed in the holder and labeled. 
2. The wells were marked as one for blank, one for negative control and two for standard 
serum in duplicate and the rest for samples. 
3. The samples were diluted in sample dilution buffer with rheumatoid factor-absorbent. The 
rheumatoid factor-absorbent was first diluted in dilution buffer as 1:4 to which samples 
were added and diluted as 1:100.  
4. Then, 100μl of diluted patient samples, controls and standard serum were put into their 
respective wells. 
5. The plate was incubated at 37ºC for 60 minutes in a moist chamber. 
6. After incubation, the plate was washed well with wash buffer taking 350µl each time for 
each well for six times. 
7. Then, 100μl of IgM–conjugate was added to all wells except blank well. 
8. The plate was incubated at 37ºC for 60 minutes in a moist chamber. 
9. After incubation, the plate was washed well with wash buffer taking 350µl each time for 
each well for six times. 
10. After that, 100μl substrate solution was added to each well. 
11. The plate was again incubated at 37ºC for 60 minutes in a moist chamber. 
12. Finally, 100μl of stop solution was added into all wells and mixed well for stopping the 
reaction. 
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Reading 
The OD (optical density) reading was taken within 60 minutes at 405 nm. The reference wave 
length was at 650 nm. 
 
Calculation  
 
The test was valid if -  
i. The substrate blank had an OD < 0.25. 
ii. The negative control was negative. 
iii. The mean OD value of the standard serum after subtraction of blank was within the 
validity range, which was given on the lot specific quality control certificate of the kit.  
iv. The variation of OD values of the standard serum was not higher than 20%. 
 
Interpretation 
The negative control and standard serum reading were taken and calculations were done. 
If the test was valid the OD values of the samples were entered in the excel sheet. 
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Leptospira IgG ELISA (Virion serion, Serion Immundiagnostics, Wurzburg, Germany) 
Procedure 
1. The microwells were taken out and placed in the holder and labeled. 
2. The wells were labeled as one for blank, one for negative control and two for standard 
serum in duplicate and the rest for samples. 
3. The samples were diluted in sample dilution buffer to get a final dilution of 1:100.  
4. Then, 100μl of diluted patient samples, controls and standard serum were put into their 
respective wells. 
5. The plate was then incubated at 37ºC for 60 minutes in a moist chamber. 
6. The plate was washed well with wash buffer taking 350µl each time for each well for six 
times. 
7. After that, 100μl of IgM–conjugate was added to all wells except blank. 
8. The plate was incubated at 37ºC for 60 minutes in a moist chamber. 
9. It was washed well with wash buffer taking 350µl each time for each well for six times. 
10. Then, 100μl substrate solution was added to each well. 
11. The plate was incubated at 37ºC for 60 minutes in moist chamber. 
12. Finally, 100μl of stop solution was added into all wells and mixed well for stopping the 
reaction. 
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Reading 
The OD reading was taken within 60 minutes at 405 nm against substrate blank, reference 
wave length was at 650 nm. 
 
Calculation  
 
The test was valid if -  
i. The substrate blank had an OD < 0.25. 
ii. The negative control was negative. 
iii. The mean OD value of the standard serum after subtraction of blank was within the 
validity range, which was given on the lot specific quality control certificate of the kit. 
iv. The variation of OD values of the standard serum was not higher than 20%. 
 
Interpretation 
The negative control and standard serum reading were taken and calculations were done. 
If the test was valid the OD values of the samples were entered in the excel sheet. 
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Leptospira IgM ELISA (InBios, InBios International Inc, Seattle, WA) 
Procedure 
1. The microtitre wells were taken out and labeled. 
2. Positive and negative controls were assayed in duplicate. So, two wells were taken for 
positive control, two wells for negative control and other wells were marked for samples.  
3. The test sera were diluted to 1:100 by using the sample dilution buffer and mixed 
thoroughly. 
4. Then, 100µl of the 1/100 diluted test sera and controls were put in each well. 
5. The plate was incubated at 37ºC for 60 minutes in a moist chamber. 
6. It was washed well with wash buffer taking 350µl each time for each well for six times. 
7. After that, 100μl of HRP conjugate was added to each well. 
8. The plate was incubated at 37ºC for 60 minutes in a moist chamber. 
9. It was washed well with wash buffer taking 350µl each time for each well for six times. 
10. Then, 150µl of EnWash solution was added per well into all wells. 
11. The plate was incubated at 20-250C for 5 minutes. 
12. It was washed well with wash buffer taking 350µl each time for each well for six times. 
13. Then, 100µl of liquid TMB substrate was added into all wells. 
14. The plate was again incubated at 20-25°C for 10 minutes. 
15. In the end, 50µl of stop solution was added into all wells and incubated at room 
temperature for 1 minute. 
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Reading 
The readings were taken at the wave length of 450nm.  
 
Calculation 
The test was valid if  
i. OD of Negative control < 0.1 
ii. OD of Positive control > 0.5 
iii. Discrimination capacity which is expressed as the ratio of  
OD of positive control (PC)/ OD of negative control (NC) ≥ 5. 
 
Interpretation 
The negative control and positive control readings were taken and calculations were done. 
If the test was valid the OD values of the samples were entered in the excel sheet. 
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Scrub typhus IgM ELISA (Inbios, Inbios International Inc, Seattle, WA) 
Procedure 
1. The microtitre wells were taken out, put in the holder and labeled. 
2. Positive and negative controls were assayed in duplicate. So two wells for positive 
control, two wells for negative control and other wells were marked for samples.  
3. The test sera were diluted to 1:100 by using the sample dilution buffer and mixed 
thoroughly. 
4. Then, 100µl of the 1/100 diluted test sera and controls were put in each well. 
5. The plate was incubated at 37ºC for 60 minutes in a moist chamber. 
6. It was washed well with wash buffer taking 350µl each time for each well for six times. 
7. After that, 100μl of HRP conjugate was added to each well. 
8. The plate was incubated at 37ºC for 60 minutes in a moist chamber. 
9. It was washed well with wash buffer taking 350µl each time for each well for six times. 
10. Then, 150µl of EnWash solution was added per well into all wells. 
11. The plate was incubated at 20-250C for 5 minutes. 
12. It was washed well with wash buffer taking 350µl each time for each well for six times. 
13. To each well 100µl of liquid TMB substrate was added. 
14. Then, the plate was incubated at 20-25°C for 10 minutes. 
15. Finally, 50µl of stop solution was added into all wells and incubated at room temperature 
for 1 minute. 
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Reading 
The readings were taken at the wave length of 450nm. 
 
Calculation 
The test was valid if  
i. OD of Negative control < 0.1 
ii. OD of Positive control > 0.5 
iii. Discrimination capacity which was expressed as the ratio of  
OD of positive control (PC)/ OD of negative control (NC) ≥ 5 
 
Interpretation 
The negative control and positive control readings were taken and calculations were done. 
If the test was valid the OD values of the samples were entered in the excel sheet. 
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Polymerase Chain Reaction 
Serum samples of the patients were used for PCR. 
DNA extraction from serum samples: 
DNA was extracted using the QIAamp blood mini kit (Qiagen, Hilden, Germany) from the 
serum samples as per the manufacturer‟s instructions for blood and body fluid protocol with 
the help of spin column. The method used was as follows -  
1. Qiagen Proteinase K (20µl) was taken in the bottom of a 1.5 ml microcentrifuge tube. 
2. To it, 200μl serum sample was added. 
3. Then, 200μl Buffer AL (lysis buffer) was added to the sample in the same tube. 
4. These substances were mixed well by pulse vortexing for 15 seconds.  
5. The tube was incubated at 560C for 10 minutes. 
6. After this, the tube was briefly centrifuged to remove the drops from inside the lid. 
7. To the tube, 200μl of absolute alcohol was added. 
8. Again, it was mixed well by pulse vortexing for 15 seconds. 
9. Then, the tube was briefly centrifuged to remove the drops from inside the lid. 
10. The mixture was placed in the QIAamp spin column with a 2 ml collection tube without 
wetting the rim and the cap was closed. 
11. The spin column was centrifuged at 8000 rpm for 1 minute.  
12. The QIAamp spin column was placed in a clean 2 ml collection tube and the collection 
tube containing the filtrate was discarded. 
13. The QIAamp spin column was carefully opened and 500μl Buffer AW1 (Wash buffer) 
was added to it without wetting the rim and the cap was closed. 
14. It was centrifuged at 8000 rpm for 1 minute. 
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15. The QIAamp spin column was placed in a clean 2 ml collection tube and the collection 
tube containing the filtrate was discarded. 
16. The QIAamp spin column was carefully opened and 500μl Buffer AW2 (Wash buffer) 
was added without wetting the rim and the cap was closed. 
17. It was centrifuged at full speed of 14,000 rpm for 3 minutes.  
18. The QIAamp spin column was placed in a clean 1.5 ml microcentrifuge tube and the 
collection tube containing the filtrate was discarded.  
19. The QIAamp spin column was carefully opened and 200μl Buffer AE (eluting buffer) was 
added to it.  
20. The tube was incubated at room temperature for 1 minute. 
21.  It was then centrifuged at 8000 rpm for 1 minute and the spin column was discarded. 
22. The 1.5 ml centrifuge tube contained DNA which was labeled and stored at -700C in two 
aliquots – one aliquot was used for PCR and the other one was used for LAMP assay. 
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Polymerase Chain Reaction for leptospirosis 
The DNA was stored at -70
0
C. 
Nested PCR 
Gene: rrs gene 
Amplicon size: 547bp 
The primer sequence used for nested PCR to detect a 547bp fragment of the rrs gene of  
pathogenic leptospira was as described by Boonsilp et al (9). The primer sequence was as 
given below in table 4.4  
Table 4.4: Primer used for Leptospira PCR 
Primer Sequence 
rrs-outer-F: 5'-CTCAGAACTAACGCTGGCGGCGCG-3' 
rrs-outer-R 5'-GGTTCGTTACTGAGGGTTAAAACCCCC-3' 
rrs-inner-F 5'-CTGGCGGCGCGTCTTA-3' 
rrs-inner-R 5'-GTTTTCACACCTGACTTACA-3' 
 
The thermal cycler „Veriti‟ 96 well Fast Thermal Cycler (Applied Biosystems, Foster City, 
CA, USA) was used to optimize the primer concentrations required.   
Reaction Volume for PCR: 50μl in each run 
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Standardisation of PCR:  
The PCR was standardised using the control strains of Leptospira interrogans obtained from 
Regional Medical Research Centre, Port Blair, India. The strains obtained were as follows 
(table 4.5) 
Table 4.5: Strains of leptospira used for standardisation of PCR  
Genomospecies  Serogroup  Serovar  Strain  
Leptospira interrogans Pomona  Pomona Pomona 
Leptospira interrogans Icterohaemorrhagiae  Icterohaemorrhagiae RGA 
Leptospira interrogans Sejroe  Hardjo Hardjo  
 
Standardisation of PCR was done by varying magnesium chloride concentrations from 2mM 
to 5mM with increasing 0.5 mM / reaction. The primer concentration was also varied with the 
different concentration of 5pmol, 10pmol and 20pmol of each primer. 
Subsequently, the optimal conditions were determined. 
It was a nested PCR. 
In the first cycle, the reaction mixture contained 2X PCR mix (Thermo Fisher Scientific, 
Marietta, USA), 20 pmol of each of the primers, 4mM Magnesium chloride and water along 
with 5µl of DNA. 
In the second cycle, the reaction mixture contained 2X PCR mix (Thermo Fisher Scientific, 
Marietta, USA), 20 pmol of each of the primers, 4mM Magnesium chloride and water along 
with 5µl of the amplified product from the first cycle. 
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Table 4.6: Cycling parameters 
Run Temperature Time Cycle 
First Run 95°C 2 minutes 1 cycle 
95°C 10 seconds  
40 cycles 67°C 15 seconds 
72°C 30 seconds 
72°C 7 minutes 1 cycle 
Second Run 95°C 2 minutes 1 cycle 
95°C 10 seconds  
40 cycles 55°C 15 seconds 
72°C 30 seconds 
72°C 7 minutes 1 cycle 
 
 
Detection of the amplicon: The rrs gene amplified product (10µl) was electrophoresed in a 
submarine electrophoresis unit using a 2% agarose gel containing ethidium bromide 
(10µg/ml). The PCR product was visualized using a gel documentation system (Bio-Rad 
Laboratories, Hercules, CA, USA). 
The positive and negative controls of each run were checked and the run was validated. Then 
the results of the samples were taken and entered in the excel sheet. 
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Genomic Sequencing 
Randomly, two amplified products for rrs gene were subjected to sequencing reaction to 
confirm the appropriateness of the target amplified. The sequencing procedure includes the 
following steps -  
Pre – Clean up 
It was done according to the protocol given by HighPrep PCR (Magbio Genomics, Inc. 
Gaithersburg, Canada) 
1. The HighPrep PCR reagent was brought to room temperature for at least 30 min before 
use. It was shaken thoroughly to fully resuspend the magnetic beads. 
2. To 20µl of PCR amplicon, 36µl of HighPrep PCR reagent was added and mixed 
thoroughly with a pipette 6-8 times in a 1.5 ml eppendorf tube. 
3. It was incubated at room temperature for 5 minutes. 
4. The sample tubes were placed on a magnetic separation device for 3 minutes until the 
solution clears. 
5. With the samples still on the magnetic separation device, the supernatant was removed 
and discarded with a pipette. 
6. Then, 200µl of 70% ethanol was added to each sample tube without removing the tubes 
from the magnetic separation device. 
7. The tube was incubated on the magnetic separation device for 30 seconds at room 
temperature. 
8. The clear supernatant was removed and discarded with a pipette. 
9. Again, 200µl of 70% ethanol was added to each sample tube without removing the tubes 
from the magnetic separation device. 
10. It was incubated on the magnetic separation device for 30 seconds at room temperature. 
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11. The clear supernatant was removed and discarded with a pipette. 
12. The beads were dried by incubating at room temperature for 5 minutes with the plate still 
on the magnetic separation device. 
13. The samples were removed from the magnetic separation device.  
14. Finally, 40 µl of water was added to each tube and it was mixed thoroughly five times 
with a pipette. 
15. The samples were placed back on the magnetic separation device and incubated at room 
temperature for 1 minute. 
16. The elute was taken in new tubes and used for PCR for sequencing and gel 
documentation to detect the product. 
 
PCR for Sequencing 
Reaction volume: 10µl 
The reaction mixture contained RR mix, buffer, 1 pmol concentration of one primer (either 
forward or reverse), 2µl of the product DNA after pre-clean up, and water. 
 
Table 4.7: Cycling parameters 
Temperature Time Cycle 
96°C 15 seconds  
25 cycles 50°C 20 seconds 
60°C 4 minutes 
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Post Clean up 
1. DTR reagent (10µl) was taken in a 1.5ml eppendorf tube.  
2. To it, 10µl of amplified PCR product and 40µl of 85% ethanol were added and mixed 
well ten times with a pipette. 
3. The tube was incubated for 5 minutes at room temperature on the magnetic separation 
device. 
4. The supernatant was discarded with a pipette. 
5. Then, 100µl of 85% ethanol was added to each tube keeping it on the magnetic separation 
device without mixing.  
6. It was incubated for 2 minutes at room temperature on the magnetic separation device and 
the supernatant was discarded. 
7. Again, 100µl of 85% ethanol was added to each tube keeping it on the magnetic 
separation device without mixing. 
8.  It was incubated for 2 minutes at room temperature on the magnetic separation device 
and the supernatant was discarded. 
9. The cap was opened and the beads were allowed to dry by incubating at room 
temperature for 10 minutes. 
10. Finally, 40µl of injection solution was added to it and mixed well. 
11. The tubes were incubated at room temperature for 5 minutes on the magnetic separation 
device. 
12. The clear supernatant was taken and loaded in the sequencing plate. 
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Sequencing  
The sequencing plate was loaded in the sequencer to obtain the genomic sequences. The ABI 
310 Genetic analyser (Applied Biosystems, Foster City, CA, USA) was used to enumerate the 
sequences.  
 
Analysis 
The sequence obtained was visualised and edited using Finch TV (Perkin Elmer, Seattle, 
WA) to attain the final sequence for analysis. 
The homology of the sequence obtained with that of the existing leptospira sequence in the 
Gene Bank was performed using the basic local alignment search tool (BLAST, available 
from www.ncbi.nlm.nih.gov/BLAST) programme with the available standard reference 
sequences in the Gene Bank for homology.  
The Megablast format of this programme which searches for highly similar sequences was 
used for analysing the sequences. 
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LAMP (loop – mediated isothermal amplification) assay for leptospira 
The LAMP assay was performed using the protocol and primer sequence provided by Dr 
WM Ching, Senior Scientist, Naval Medical Research Centre, Silver Spring, MD, USA. As 
the primer sequence has not yet been published, the primer sequence is not revealed. 
However, it has been validated by Dr. Ching‟s research group. 
 
Target: LipL32, LipL41 gene 
Primer Mix preparation - 3µl 
Table 4.8: Primer concentration used in LAMP assay 
Primer Stock Concentration Volume added (µl) 
L32-F3 25 0.2 
L32-B3 25 0.2 
L32-FIP 100 0.4 
L32-BIP 100 0.4 
L32-LF 100 0.2 
L32-LB 100 0.2 
L41-F3 25 0.2 
L41-B3 25 0.2 
L41-FIP 100 0.4 
L41-BIP 100 0.4 
L41-LB 100 0.2 
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Reaction volume - 25µl 
Master mix preparation: for 5 ml 
Table 4.9: Master mix for LAMP 
Component  Volume 
10X Thermopol (NEB) 1 ml 
Betaine (5M) 1.6 ml 
Magnesium sulphate (1M) 60µl 
Each dNTP (100mM) 140µl  
Water  1.78 ml 
 
Components of the LAMP Reagent: per 25μL reaction 
Table 4.10: Components of LAMP assay 
Component Volume 
2x Master mix 12.5μl 
Primer mix 3μl 
Water 3.5µl 
Bstpolymerase (from NEB) 1μl (8 units)  
 
DNA Sample 5µl 
 
 
In each run a positive control which was Leptospira interrogans strain Icterohaemorrhagiae 
obtained from Regional Medical Research Centre, Port Blair, India and a negative control 
were used. 
Cycling condition: 63
o
C for 60 minutes. 
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Detection of the LAMP products:  
1. Visual detection for turbidity –  
The positive sample should be turbid while the negative sample should be clear. 
2. Centrifugation – The tube was centrifuged at 14,000rpm for 1 minute for pellet formation. 
The positive sample had a tear – drop pellet while in the negative sample no pellet was seen. 
3. Gel documentation: It was done by gel electrophoresis using a 2% agarose gel containing 
ethidium bromide (10µg/ml). The product was visualized using a gel documentation system 
(Bio-Rad Laboratories, Hercules, CA, USA). 
The positive reaction had bands while the negative reaction had no band. The multiple 
banding pattern in LAMP assay was compared with that of the control strain. 
 
The readings for the positive and negative controls were taken and the run was validated. 
Then the results for the samples were taken and entered in the excel sheet. 
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Data analysis 
The OD values of the ELISA were all entered in the excel spreadsheet (Microsoft Office, 
Redmond, Washington, USA). The geometric mean (GM) and the standard deviation (SD) 
were calculated using excel spreadsheet. The cut-off was calculated as GM+3SD. 
All samples which were positive by PCR or LAMP twice were considered positive by the 
respective tests.  
Case definition: The case definition used in this study included the samples which were 
positive by PCR or LAMP or fulfilling modified Faine‟s (109) criteria for leptospirosis were 
taken as cases of leptospirosis. 
All data was entered in the clinical proforma and then in the master-table in excel 
spreadsheet. 
Statistical analysis 
The statistical analysis of the clinical data was done using STATA version 13. The data were 
summarised using mean along with standard deviation for continuous variables, and 
frequency along with percentages for categorical variable. Chi square test was used to check 
the categorical variables association and p value <0.05 was taken as significant. 
The diagnostic accuracies (sensitivity and specificity) of ELISA, PCR, LAMP were evaluated 
using Latent Class Analysis (LCA). The LCA was done to evaluate the true status of disease 
using the available three tests. The derived result from this technique was considered as gold 
standard and diagnostic accuracies were given.  
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I. For Validation of cut –off for ELISA 
A. Determination of cut – off in healthy individuals 
  
 
 
 
 
 
 
B. Determination of diagnostic cut - off 
                                                   
 
                                              
                                                      
 
 
                                                                                          
 
 
                                                                                                         
 
   
 
Plasma samples from healthy blood donors 
IgM ELISA for leptospira and scrub typhus  
GM + 3 SD calculated 
Serum samples collected from  
50 patients with scrub typhus having eschar* 
20 patients with sepsis 
20 patients with enteric fever 
17 patients with dengue 
17 patients with malaria 
IgM ELISA leptospira and scrub typhus 
GM + 3SD calculated 
* Was not used for validation of scrub typhus ELISA 
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II. Evaluation of tests for diagnosis of leptospirosis 
 
  
 
 
 
 
 
 
 
                                                   
 
                                                                                                    
 
                                              
                                                   
                                                  
 
 
                                                   
                                                     
 
                                                  
                                                                                                                                                           
Adult patient ≥18 years admitted with fever ≤15 days  
Blood culture, eschar and malaria negative individuals were included 
Clinical information, informed consent and serum collected 
DNA extraction done Serum subjected IgM ELISA for leptospira and 
scrub typhus 
PCR and LAMP assay for leptospirosis 
Sequencing done for 2 samples 
(PCR and LAMP positive) 
Convalescent serum collected after 7 days  
IgM ELISA done for leptospira and scrub typhus 
BLAST analysis 
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                                               Results 
 
I. For Validation of cut –off for ELISA 
A. Determination of cut – off in healthy individuals 
  
 
 
 
 
 
 
 
B. Determination of diagnostic cut - off 
                                                   
 
 
 
 
 
 
                                              
                                                      
100 plasma samples from healthy blood donors 
IgM ELISA for leptospira  
15 PanBio units  
Serum samples collected from other similar illness 
IgM ELISA for scrub typhus  
0.4 OD in InBios ELISA 
IgM ELISA for leptospira  
Cut-off ≥20 PanBio 
units  
IgM ELISA for scrub typhus  
Cut-off ≥0.5 OD in InBios 
ELISA 
20 serum samples 
Similar OD value 
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II. Evaluation of tests for diagnosis of leptospirosis 
  
 
 
 
 
 
 
 
                                                   
 
                                                                                                    
 
                                              
                                                   
                                                  
 
 
                                                   
                                                     
 
* Two more samples were positive for IgM ELISA for scrub typhus. One sample was 
positive by both PCR and LAMP assay and the other was positive only by the LAMP assay.                                    
                                                                                                                                                  
150 adult patients admitted with fever ≤15 days recruited 
IgM ELISA for leptospira 
only Positive = 40 
 
PCR, LAMP and ELISA 
Positive = 3 
 
Sequencing done 
for 2 samples 
Convalescent serum collected for 
32 patients after 7 days  
IgM ELISA done for leptospira  
Positive = 10 
 
Confirmed as 
Leptospira interrogans 
LAMP only 
Positive = 7 
PCR only 
Positive = 2 
Only IgM for 
leptospirosis 
Positive = 20 
IgM ELISA for 
scrub typhus 
Positive = 20 * 
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The plasma samples from healthy blood donors were used for determination of cut-off value of optical density (OD) for the different ELISAs 
and the same is as given below (table 5.1)  
Table 5.1: ELISA cut – off value – Healthy blood donors 
 Leptospira PanBio 
IgM 
(PanBio units) 
Leptospira Virion 
serion IgM (OD) 
Leptospira Virion 
serion IgG (OD) 
Leptospira InBios 
IgM (OD) 
Scrub typhus 
InBios IgM (OD) 
Geometric Mean (GM) 3.974 0.198 0.483 0.017 0.072 
Standard deviation (SD) 3.5 0.157 0.367 0.035 0.082 
2 SD 7 0.314 0.734 0.07 0.164 
3 SD 10.5 0.471 1.101 0.105 0.246 
GM + 2 SD 10.974 0.512 1.217 0.087 0.236 
GM + 3 SD 14.474 0.669 1.584 0.122 0.318 
Cut-off 15 0.7 1.6 0.2 0.4 
 
Serum samples from 20 healthy donors had similar OD values as the plasma. 
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The ELISA was validated using serum samples from patients having scrub typhus with eschar (n=50), sepsis (n=20), enteric fever confirmed by 
blood culture (n=20), malaria (n=17) and dengue (n=17). Table 5.2 shows the final cut-off determined after proper validation of the ELISA. 
Samples from patients with scrub typhus with eschar were not used for validation of scrub typhus IgM ELISA. 
Table 5.2: Diagnostic cut-off for ELISA 
 Leptospira PanBio 
IgM  
(PanBio units) 
Leptospira Virion 
serion IgM (OD) 
Leptospira Virion 
serion IgG (OD) 
Leptospira InBios 
IgM (OD) 
Scrub typhus InBios 
IgM (OD) 
Geometric Mean (GM) 3.771 0.145 0.699 0.063 0.09 
Standard deviation (SD) 5.141 0.129 0.666 0.313 0.127 
2 SD 10.282 0.258 1.332 0.626 0.254 
3 SD 15.423 0.387 1.998 0.939 0.381 
GM + 2 SD 14.053 0.403 2.031 0.689 0.344 
GM + 3 SD 19.194 0.532 2.697 1.002 0.471 
 Final Cut-off 20 0.7 2.7 1 0.5 
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For evaluation of the tests for diagnosis of leptospirosis, 150 patients with fever ≤15 days 
were recruited. Among 150 patients, 97 (64.7%) were male and 53 (35.3%) were female 
(Figure 5.1) 
 
Figure 5.1: Sex distribution of the patients recruited 
Among the patients recruited 42(28%) were between 18-30 years, 40(26.7%) were between 
31-45 years, 45(30%) were between 46-60 years and 25(16.7%) were above 60 years of age 
(Figure 5.2) 
 
Figure 5.2: Age distribution of the study patients  
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Majority of the patients recruited were from Tamil Nadu (60%) and Andhra Pradesh (31.3%) 
(Figure 5.3) 
 
Figure 5.3: Geographical distribution of the patients recruited  
Out of the recruited patients 66 (44%) were farmers, followed by 32 (21%) housewives and 
18 (12%) professionals (Figure 5.4). 
 
Figure 5.4: Occupation of the study patients  
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The serum samples of 150 patients recruited in the study were tested for antibodies to 
leptospira by IgM ELISA (PanBio Ltd), PCR for rrs gene for leptospira and LAMP assay for 
LipL41 and LipL32 genes for leptospira. 
Among these patients, totally, 43 were positive for antibodies by IgM ELISA, 10 were 
positive by LAMP assay and 5 were positive by PCR. Of these, 3 samples were positive by 
all 3 tests (Figure 5.5).  
 
Figure 5.5: Results of three tests used for leptospirosis diagnosis 
All these 52 patients fulfilled the case definition for leptospirosis (either positive by a 
molecular assay or fulfilled modified Faine‟s criteria). 
Among the ELISA positive samples, the values had a range 20 to 54 PanBio units           
(mean = 25.4, median = 23, mode =21) 
Among the samples negative for leptospirosis the ELISA range was 1 to 15 Panbio units 
(mean = 3.3, median = 3, mode = 2). 
IgM ELISA 
40 
LAMP 
7 
PCR 
2 
3 
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Convalescent serum samples were collected from 32 patients after 7 or more days of 
collection of initial serum and were tested for IgM antibodies to leptospira by ELISA. 
Among them, 10 patients continued to be positive for IgM antibodies. However, none 
seroconverted. 
All the patients recruited had fever (≥100º F).  
The number of patients with their duration of fever with which they presented to our hospital 
is shown in Figure 5.6. 
 
Figure 5.6: Duration of fever in study population 
Among these patients, 49(32.67%) had chill and rigor of which 19(36.54%) had leptospirosis 
while 30(30.61%) did not have leptospirosis (p = 0.461). 
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The most common symptoms were myalgia, headache, vomiting, and abdominal pain. 
Among the patients recruited, 60(40%) patients had myalgia, of which 25(48.08%) had 
leptospirosis and 35(35.71%) were without leptospirosis. (Figure 5.7). 
      
Figure 5.7: Myalgia in patients with and without leptospirosis 
Also, 46(30.67%) patients had headache of which 19(36.54%) had leptospirosis and 
27(27.55%) did not have leptospirosis (Figure 5.8). 
      
Figure 5.8: Headache in patients with and without leptospirosis 
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The common gastrointestinal symptoms were abdominal pain in 33(22%), diarrhoea in 
21(14%) and vomiting and nausea in 71(47.33%) patients (table 5.3). Abdominal pain was 
seen in 12(23.08%) patients with leptospirosis and 21(21.43%) patients without leptospirosis. 
Loose stool was present in 8(15.38%) patients of leptospirosis and 13(13.27%) patients 
without leptospirosis. Nausea and vomiting was seen in 22(42.31%) leptospirosis patients and 
49(50%) of other patients. However, of the leptospirosis patients 40(76.92%) did not have 
abdominal pain, 44 (84.62%) did not have loose stool and 30(57.69%) did not have nausea or 
vomiting. Abdominal pain, loose stool and nausea and vomiting were not significantly higher 
in patients with leptospirosis. Amongst the other patients without leptospira infection, 
77(78.57%) did not have abdominal pain, 85(86.73%) did not have loose stool and 49(50%) 
did not have nausea or vomiting. 
 
Table 5.3: Distribution of gastrointestinal symptoms in patients with and without 
leptospirosis 
Symptoms  Patients without 
leptospirosis 
Patients with 
leptospirosis 
p value 
Abdominal pain (n=33) 21(21.43%) 12(23.08%) 0.817 
Loose stool (n=21) 13(13.27%) 8(15.38%) 0.722 
Nausea and vomiting (n=71) 49(50%) 22(42.31%) 0.369 
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The common respiratory symptoms were dry cough in 14(9.33%) patients, cough with 
expectoration in 23(15.44%) patients, respiratory distress in 31(20.67%) patients and chest 
pain in 1(0.67%) patients. The only patient having chest pain had leptospirosis. Dry cough 
was seen in 3(5.77%) patients with leptospirosis and 11(11.22%) patients without 
leptospirosis. Cough with expectoration was present in 12(23.08%) patients of leptospirosis 
and 11(11.22%) patients without leptospirosis. Respiratory distress was seen in 13(25%) 
leptospirosis patients and 18(18.37%) of other patients. However, of the leptospirosis patients 
49(94.23%) did not have dry cough, 40(76.92%) did not have expectoration and 39(75%) did 
not have respiratory distress. Cough, expectoration, respiratory distress and chest pain were 
not significantly higher in patients with leptospirosis. In those without leptospira infection, 
87(88.78%) did not have cough, 86(87.75%) did not have expectoration and 80(81.63%) did 
not have respiratory distress.  
 
Table 5.4: Distribution of respiratory symptoms in patients with and without 
leptospirosis 
Symptoms  Patients without 
leptospirosis 
Patients with 
leptospirosis 
p value 
Dry cough (n=14) 11(11.22%) 3(5.77%) 0.274 
Cough with expectoration 
(n=23) 
11(11.22%) 12(23.08%) 0.055 
Respiratory distress (n=31) 18(18.37%) 13(25%) 0.340 
Chest pain (n=1) 0(0%) 1(1.92%) 0.168 
 
 
95 
 
In patients with leptospirosis, the urine output was significantly reduced as shown in Figure 
5.9. The decreased urine output was seen in 15(28.85%) patients with leptospirosis but in 
only 13(13.27%) patients without leptospirosis. 
      
Figure 5.9: Distribution of urine output in the patients with and without leptospirosis 
Among the patients recruited, 17(11.33%) had maculopapular rash of which 4(7.69%) had 
leptospirosis and 13(13.27%) did not have leptospirosis (Figure 5.10).  
      
Figure 5.10: Distribution of rash in the patients recruited 
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The central nervous system involvement was seen in severe disease in 24(16%) patients of 
which 5(9.62%) had leptospirosis while 19(19.39%) did not have leptospirosis (p = 0.120). 
The symptoms were seizure 7(5%), altered sensorium 14(9%), delirium 2(1.33%) and 
diplopia 1(0.67%) (Figure 5.11).  
 
Figure 5.11: Central nervous system manifestations in the patients recruited 
Among the patients recruited only 13(8.67%) had bleeding manifestations (Figure 5.12) of 
which 4(7.69%) had leptospirosis and 9(9.18%) did not have leptospirosis (p = 0.757).  
 
Figure 5.12: Bleeding manifestations in the study patients 
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Among the patients who had leptospirosis 31(59.61%) had jaundice with increased bilirubin 
(>1mg/dl) and 21(40.38%) had normal bilirubin (≤1mg/dl). Among the patients who did not 
have leptospirosis 56(57.14%) had jaundice while 42(42.85%) did not have jaundice. Hence, 
presence of jaundice is not significant in leptospirosis patients (p = 0.052) (table 5.5) 
Table 5.5: Bilirubin in patients with and without leptospirosis 
Bilirubin  Without leptospirosis Leptospirosis  
Bilirubin ≤1mg/dl 42 21 
Bilirubin >1-3mg/dl 26 6 
Bilirubin >3-10mg/dl 25 16 
Bilirubin >10mg/dl 5 9 
Total  98 52 
In patients with leptospirosis only 6(20%) had bilirubin 1-3mg/dl while 25(48%) had 
moderate/severe (>3mg/dl bilirubin) jaundice while in patients without leptospirosis 
26(26.5%) had mild and 31(31.6%) had moderates/severe jaundice (Figure 5.13). Severe 
jaundice is significantly related to leptospirosis. 
     
Figure 5.13: Severity of jaundice in patients of leptospirosis 
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In the patients recruited, 56(37.3%) had raised creatinine level (>1.4mg/dl). Renal damage as 
indicated by raised creatinine level is not significantly higher in patients with leptospirosis as 
22(42.3%) patients with leptospirosis had renal damage whereas 34(34.69%) patients had 
renal damage without leptospirosis as shown in table 5.6 (P = 0.243) 
Table 5.6: Creatinine levels in patients recruited 
Creatinine Without leptospirosis Leptospirosis  
Creatinine ≤1.4mg/dl 64 30 
Creatinine >1.4-2.5mg/dl 11 2 
Creatinine >2.5-4mg/dl 10 7 
Creatinine >4 mg/dl 13 13 
Total  98 52 
There were 20 patients with leptospirosis who had creatinine >2.5mg/dl whereas 23 patients 
without leptospirosis had creatinine >2.5mg/dl as compared to 2 patients of leptospirosis and 
11 patients of other diseases with creatinine >1.4-2.5mg/dl (Figure 5.14) 
      
Figure 5.14: Severity of renal damage in patients with leptospirosis 
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Among the patients 31(20.67%) patients had acute respiratory distress syndrome, of which 
13(25%) had leptospirosis and 18(18.37%) did not have leptospirosis (Figure 5.15) 
      
Figure 5.15: Acute respiratory distress syndrome in study population 
In the study population, 97(64.6%) had a fall in the blood platelet count (<150000/mm
3
 
blood). It was reduced in 40(76.92%) patients with leptospirosis and 57(58.16%) patients 
without leptospirosis (Figure 5.16) 
      
Figure 5.16: Platelet count of the patients recruited 
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A nested PCR was done for the detection of rrs gene of leptospira. The resulting amplicon is 
547bp. 
 
Figure 5.17: Gel picture of the PCR for leptospirosis  
A ladder of 100bp was used as a reference for calculation of the base pair. The positive 
control (PC) was the control strain of Leptospira interrogans serovar Icterohaemorrhagiae, 
which showed a band at 547bp for rrs gene. The negative control (NC) did not show any 
band. As both the controls were satisfactory, the readings for the samples were taken. 
The sample 3, sample 38 and sample 48 showed bands at 547bp and were considered positive 
for rrs gene for leptospira.  
The sample 1, sample 10, sample 24, sample 40, sample 42, sample 46 had no bands and 
were taken as negative for leptospirosis. 
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A loop – mediated isothermal amplification assay (LAMP) was done for detection of LipL32 
and LipL41 genes of leptospira.  
 
Figure 5.18: Gel picture of the LAMP assay 
A ladder of 100bp was used as a reference for calculation of the base pair. The positive 
control (PC) was the control strain of Leptospira interrogans serovar Icterohaemorrhagiae, 
which showed a LAMP band. The negative control (NC) did not show any band. As both the 
controls were satisfactory, the readings for the samples were taken. For the samples, the 
reading were taken by comparing it with the banding pattern of the control strain.  
The sample 3, sample 48, sample 85, sample 92 had bands similar to the control strain band 
and were taken as positive by LAMP assay. The samples 43, sample 44, sample 62, sample 
65, sample 72, sample 73, sample 86 and sample 121 did not have any band and were taken 
as negative by LAMP assay. 
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Evaluation of the three tests 
By using latent class analysis for the three tests ELISA, PCR and LAMP for diagnosis of 
leptospirosis it was found that there is a prevalence of 2% of leptospirosis among the patients 
recruited. 
Table 5.7: Result of diagnostic assay 
ELISA PCR LAMP Positives 
+ + + 3 
+ - - 40 
- + - 2 
- - + 7 
 
As the prevalence is very low, the sensitivity of the tests show that all the three tests are 
highly sensitive (table 9).However, the specificity is highest for PCR with 98.64%, followed 
by LAMP 95.24% and least for ELISA 72.79% as shown in table 5.8. 
Table 5.8: Performance of the tests for diagnosis of leptospirosis 
 Test   
Sensitivity  ELISA 100% 
PCR 100% 
LAMP 100% 
Specificity  ELISA 72.79% 
PCR 98.64% 
LAMP 95.24% 
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So, it is evident from the table that LAMP assay has specificity very close to that of PCR. 
Utility of LAMP assay 
It was seen that LAMP assay was positive for all 10 (100%) within the first week of illness. 
In case of PCR 3(60%) were positive in the first week of illness and other 2(40%) on 10
th
 day 
of fever. This is shown in Figure 5.19. By ELISA IgM antibodies were detectable within 7 
days of illness for 20(46.5%) and 23(53.4%) were positive between 8-15 days of fever.   
This shows that LAMP assay is a reliable test in the first week of illness and IgM ELISA is 
useful in the second week of fever. 
 
Figure 5.19: Relation between duration of fever and leptospira assay performance 
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Sequencing was done for sample 38 and 48. The sequence of sample 38 is shown in Figure 
5.20 below. 
 
 
Figure 5.20: Genomic sequence of sample 38 
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The identity of the two samples sequenced after analysis with the available sequences in 
genebank are given below in table 5.9 
Table 5.9: Identity of the sequence of the two isolates 
Identity with the strain Sample 38 
538 nucleotides 
Sample 48 
546 nucleotides 
Leptospira interrogans serovar Canicola           
 
 
 
 
 
 
          98% 
 
 
 
        97% 
 
Leptospira interrogans serovar Hebdomadis  
Leptospira interrogans serovar Zanoni  
Leptospira interrogans serovar Hardjo  
Leptospira interrogans serovar Bratislava 
Leptospira interrogans serovar Grippotyphosa 
Leptospira interrogans serovar Australis  
 
 
 
        96% 
Leptospira interrogans serovar Kremastos 
Leptospira interrogans serovar Pomona strain Pomona 
Leptospira interrogans serovar Lai 
Leptospira interrogans strain Icterohaemorrhagiae  
Leptospira interrogans strain Coppenhageni 
Leptospira interrogans serovar Hardjo-prajitno 
Leptospira kirschneri strain Grippotyphosa 
Uncultured leptospira 
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Among the patients recruited, 52(34.7%) had evidence of leptospira infection and 56( 37.3%) 
had IgM antibodies to Orientia tsutsugamushi and 22 patients had IgM antibodies to both 
leptospira and scrub typhus (Figure 5.21). 
 
Figure 5.21: Samples positive for leptospirosis and scrub typhus 
Most of the patients improved with treatment with doxycycline, ceftriaxone, azithromycin or 
a combinations of these drugs (Figure 5.22)
Figure 5.22: Antimicrobials received by the patients recruited 
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All the patients who were positive for scrub typhus or leptospira by any of the tests received 
either or in combinations of the three antimicrobials – doxycycline, ceftriaxone, azithromycin 
except one patient who received meropenem and improved in 25 days.  
Of the 150 patients recruited in the study, only 7(4.6%) succumbed to the illness. Of these 
three patients were diagnosed as leptospirosis by modified Faine‟s criteria. 
Table 5.10: Details of patients who succumbed to illness 
Patient no Clinical diagnosis Comment  
A Leptospirosis  Died within 6 hours 
B Scrub typhus Died in 48 hours 
C Acute febrile illness Died within 24 hours 
D Tuberculous meningitis Died in 7 days 
E Ventilator associated pneumonia Died in 10 days 
F Septic shock  Secondary infection 
G Acute febrile illness Died within 24 hours 
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                                             Discussion 
 
Leptospirosis is a common cause of acute febrile illness especially during the monsoon 
months. As the clinical features are non-specific the differentials considered are malaria, 
dengue, scrub typhus, rickettsial fever and typhoid fever (1). Hence, laboratory diagnosis of 
leptospirosis is essential for confirmation of the disease. The gold standard tests for diagnosis 
of leptospirosis are culture and microscopic agglutination test (MAT) which are not feasible 
as routine diagnostic tests (1). Currently the most widely used method for diagnosis of 
leptospirosis is IgM antibody detection by ELISA. In addition, molecular tests are considered 
as good as the reference test for diagnosis  (114). 
This pilot study was done to evaluate the utility of IgM ELISA, PCR and LAMP assay in the 
diagnosis of leptospirosis. A total of 150 patients who fulfilled the inclusion and exclusion 
criteria were recruited. Among the patients enrolled, 52 were taken as cases of leptospirosis 
based on the case definition adopted for this study. These included three samples positive by 
all three tests (PCR, LAMP and IgM ELISA), two samples positive by PCR for rrs gene and 
seven samples positive by LAMP assay for LipL32 and LipL41 genes and IgM antibodies to 
leptospira detected by ELISA in sera from 40 patients who fulfilled modified Faine‟s criteria. 
Fidelity of amplification of leptospira specific DNA was confirmed by sequencing the rrs 
gene product of two samples which were positive by PCR and LAMP assay. 
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Validation of ELISA 
It is recommended that cut off values for infectious disease diagnosis using serological assay 
like ELISA should be arrived at by testing sera from healthy individuals, those with proven 
disease and also others with clinically similar illness. The usage of well characterized 
archived specimens, consisting of the aforementioned groups allows rapid assessment of the 
clinical utility of the new assay (16). It is to be noted that if the cut-off is too low it will over-
estimate whereas if the cut-off is too high it will under-estimate the burden of disease in the 
given community or region.   
The prevalence of antibodies in the plasma samples of healthy blood donors was determined 
in this study. The plasma and serum samples of 20 healthy donors showed similar results, 
therefore, it was concluded that plasma values could be extrapolated to serum. Serum 
samples of patients who present with an illness like scrub typhus, sepsis, enteric fever, 
malaria and dengue (clinically indistinguishable from leptospirosis) were used to determine 
and validate the ELISA cut-off. 
Validation of a diagnostic cut-off for a serological assay is necessary in countries, especially 
South Asian and South-East Asian nations. This is because infections are a major cause of 
morbidity and mortality in these regions and is supported by evidence provided by various 
studies. In a study undertaken by Desakorn V et al from Thailand the PanBio IgM ELISA 
was evaluated by testing sera from healthy blood donors. Using the manufacturer‟s cut-off, 
which is 11 PanBio units, the sensitivity and specificity of the ELISA on paired sera was 
90.8% and 55.1% respectively.  When the cut-off was placed at 20 PanBio units, the 
sensitivity fell to76.1% whereas the specificity improved to 82.6% (115).  In another study 
done by Tanganuchitcharnchai A et al, using a cut-off of OD ≥ 0.75 for IgM antibodies by 
ELISA (Standard Diagnostics, Inc, Gyeonggi-do, Republic of Korea), a sensitivity of 95% 
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and specificity of 41% was observed in normal sera.  On validation   of the ELISA, using 
serum samples of patients with fever, the cut-off was found to be at OD of 1.7, the sensitivity 
decreased to 70% and specificity increased to 78% (116).  The results of these two studies 
prove that a cut–off for serological diagnosis of leptospirosis has to be determined prior to its 
deployment for routine identification of cases.  
In this study the diagnostic cut-off for the Leptospira PanBio IgM ELISA (PanBio Ltd, 
Brisbane, Australia) was determined to be ≥20 PanBio units. The other IgM ELSA for 
leptospira like Virion serion (Serion Immunodiagnostics, Wurzburg, Germany) and InBios 
(InBios International, Seattle, WA, USA) were also validated and an OD ≥0.7 and ≥1.0 were 
considered significant. The three different ELISA kits evaluated had three different cut-off 
values for the detection of IgM antibodies to leptospira. This demonstrates that the cut-off 
obtained for one kit cannot be used for another kit though it detects the same parameter.  
The cut-off for detection of IgG antibodies to leptospira (Virion serion, Serion 
Immunodiagnostics, Wurzburg, Germany) was high (OD ≥2.7). This may be due to high 
seroprevalence but this could not be confirmed as only one assay for detection of IgG 
antibodies to leptospira could be performed on samples used for validation. In addition, the 
cut off OD for scrub typhus IgM ELISA (InBios International, Seattle, WA, USA) was found 
to be ≥0.5 which was the same as previously described (117). 
 
Relation of clinical features of leptospirosis 
According to World Health Organisation, the case definition of leptospirosis includes an 
acute febrile illness with headache, myalgia, conjunctival suffusion, anuria/oliguria, jaundice, 
cough, haemoptysis, breathlessness, haemorrhage, rash, nausea, vomiting, abdominal pain, 
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diarrhoea and meningeal irritation (44). The above mentioned clinical features were present 
in many of the patients recruited. However, only oliguria, moderate/severe jaundice and renal 
damage were significantly related to the patients with leptospirosis in the present study (p 
value <0.05) and only 7 patients out of which 3 had leptospirosis succumbed to the illness. 
In this study among the leptospirosis patients, in addition to fever, 48.08% had myalgia, 
36.54% had headache, 28.85% had oliguria, 59.61% had raised bilirubin and 42.3% had renal 
compromise as evidenced by raised creatinine level. Other studies performed in India have 
noted similar clinical findings in patients with leptospirosis. Datta et al observed that myalgia 
was seen in 78.4% and icterus in 74.5%, headache in 41.2% and oliguria in 29.4% of 
leptospirosis patients (66). Chaudhry et al reported that the common clinical features were 
vomiting/nausea (49.4%), headache (50.5%), myalgia (52.8%), renal involvement (54%) and 
raised bilirubin (59.7%) (36). Using Modified Faine‟s criteria Debmandal et al found that the 
commonest features were headache (100%) and jaundice (93.92%), 25.23% leptospirosis 
cases had increased bilirubin (34).  
 
Modified Faine’s criteria for diagnosis of leptospirosis 
 In a leptospira study, Chauhan and co-workers, demonstrated that out of 13 cases which 
were confirmed as leptospirosis by ELISA or PCR, all fulfilled modified Faine‟s criteria 
though only 7 fulfilled Faine‟s criteria (118). This shows that Modified Faine‟s criteria is 
more suitable for Indian scenario. The reason for modification of Faine‟s criteria was that 
rainfall should be taken into account as most outbreaks of leptospirosis occur during 
monsoon. The microscopic agglutination test (MAT) is the serological reference standard but 
it is complicated and difficult test to perform. Hence, ELISA and slide agglutination test 
(SAT) which are simple and easy to perform have also been included in the criteria (109). In 
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this study all 43 samples which were IgM ELISA positive fulfilled modified Faine‟s criteria, 
including those who were scrub typhus IgM ELISA positive. The Faine‟s criteria was not 
applied as microscopic agglutination test or culture could not be performed. 
 
Evaluation of tests for diagnosis of leptospirosis 
In this pilot study the prevalence of leptospirosis was found to be low (2%), the sensitivity of 
IgM ELISA, LAMP and PCR for diagnosis of leptospirosis was 100% by latent class analysis 
(LCA). The specificity of PCR for the target rrs gene (547bp) was found to be 98.64% , that 
of LAMP assay was 95.24% using targets LipL32 and LipL41 gene whereas the specificity of 
ELISA was 72.79%. In other studies targeting the leptospira rrs gene the specificity was 
found to be between 90-100%. The sensitivity varied between 56-94.4% (8,101–103). The 
LAMP assay for leptospirosis has been evaluated by only four research groups. In a study 
done by Lin X et al the detection limit was same as PCR (100 genome equivalents) the target 
being LipL41 gene (13). Sonthayanon et al reported that with the target rrs gene and LipL41 
gene, the sensitivity was 43.6% and 37.6% and specificity was 83.5% and 90.2% respectively 
for the two targets (6). So, in comparison, this study also had a similar specificity. In another 
study conducted by Koizumi et al, the specificity of LAMP assay with rrs gene as target was 
66.7% (14). From the last two studies it is evident that LipL41 has higher specificity 
compared to rrs gene for detection of leptospira DNA by LAMP assay. In the present study 
the LAMP assay had a high specificity as it had two targets LipL32 and LipL41. This 
explains the reason of it picking up the samples which were neither picked up by PCR nor 
ELISA. Interestingly, there were two samples which were positive for rrs gene by PCR but 
not picked up by LAMP assay or IgM detection by ELISA. This may be due to the fact that 
pathogenic leptospira have two copies of rrs but a single copy of lipL32 gene (8). 
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All 10 samples positive by leptospira LAMP assay occurred in individuals whose duration of 
illness did not exceed one week. This suggests that LAMP assay is more likely to be positive 
in those with fever less than 7 days. The leptospira LAMP assay being negative for patients 
in whom illness exceeded more than a week may be due to over the counter use of antibiotics 
and disappearance or decrease in leptospira levels in blood in the second week of illness. In 
those with leptospirosis, IgM antibody levels classically start rising in the middle of first 
week and peak by 7
th
 day of illness (1). In this study, the IgM antibodies were detectable 
from 3
rd
 day of fever and the diagnosis of leptospirosis was heavily dependent on detection of 
IgM antibodies in the second week. This confirms the finding that leptospira cannot be 
detected in blood by culture or nucleic acid amplification tests like PCR or LAMP after the 
first week of illness (14).  As already described, the sensitivity of a properly evaluated 
serological assay like ELISA is high (16). So, it is a useful tool for diagnosis of leptospirosis 
in a tertiary care centre like ours. This is of great importance as most of these patients are 
referred to our hospital in the second week of illness and have not responded to treatment at 
the peripheral centres. 
Serological confirmation of a diagnosis by ELISA involves demonstration of seroconversion 
by testing for IgM and IgG antibodies. Seroconversion is said to occur when either significant 
IgG antibodies are demonstrable in convalescent sera and/ or IgM antibodies decline below 
the diagnostic threshold (119). In spite of best efforts, convalescent sera could be obtained 
from only 32 of the 150 patients (7 or more days after collection of the initial sample). 
Amongst these patients whoever had detectable antibodies in the initial serum samples (10 of 
32) continued to have IgM antibodies in the convalescent serum as detected by ELISA. As 
the IgG ELISA on paired sera could not be performed, seroconversion in the 32 patients for 
whom the same was available could not be demonstrated.  
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Co-infection 
Amongst the 43 cases of leptospirosis according to modified Faine‟s criteria, 22 had IgM 
antibodies to O. tsustsugamushi. Of these 22 patients, one patient was positive by leptospira 
PCR and LAMP whereas another was positive by LAMP assay only. These 22 patients could 
be possible cases of co-infection or cross reaction. In a study done by Sonthayanon et al, 82 
cases with serological evidence of scrub typhus (by IFA) and leptospirosis (by MAT) were 
tested by duplex PCR targeting the 16S rRNA gene of both leptospira and Orientia 
tsutsugamushi to confirm or rule out co-infection. Scrub typhus and leptospira specific 
nucleic acid was detected in 6% (5/82), whereas DNA specific only for scrub typhus was 
detected in 5% (4/82) and for only leptopsira in 46% (38/82) (71). This demonstrates that 
molecular evidence alone cannot be used to confirm or eliminate co-infection. This is 
especially true when samples are tested later in the course of the illness as from second week 
onwards serological assays are more likely to be positive. In the 22 samples with serological 
evidence of co-infection with scrub typhus and leptospirosis around 75% had fever of 
duration more than 7 days. Paired sera (acute and  convalescent serum ) was available  for  2 
of these patients and both showed diagnostically significant levels of IgM antibodies to scrub 
typhus and leptospira respectively by ELISA in paired sera. As, molecular confirmation of 
scrub typhus was beyond the scope of this study and paired sera was not available and even if 
available could not be tested for IgG antibodies, the issue of co-infection could not be 
resolved in any of these patients. However, occurance of co-infection  with scrub typhus and 
leptospirosis had been demonstrated by many research groups using serology (68–70). IgM 
antibodies to scrub typhus in the presence of an eschar combined with a dramatic response to 
fever is considered confirmation of scrub typhus (117). As per the study criteria, only those 
patients who did not have pathognomonic eschar were evaluated. 
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Limitations of the study 
The limitations of the study were that IgG antibody testing could not be done on serum 
samples of patients with suspicion of leptospirosis. Convalescent sera could be collected only 
in 32 patients. This is attributed to the fact that the patients who responded to the treatment 
seldom return for follow-up. Molecular assays for scrub typhus could not be performed on 
the serum samples which would have been helpful in resolving the problem of co-infection.  
 
To summarise,   a prospective study was conducted to compare serological and molecular 
assays for diagnosis of leptospirosis.  The findings suggest that molecular assays are more 
likely to be positive in the first week of illness whereas in the second week serological assays 
are the mainstay of diagnosis.  These preliminary findings need to be verified by larger 
community based prospective studies using more specific assays for leptospira diagnosis. 
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                              Summary and conclusion 
 
A pilot study was undertaken to prospectively evaluate the efficacy of a serological assay 
(IgM ELISA) and molecular techniques (PCR and LAMP assay) for diagnosis of 
leptospirosis in 150 clinically suspected cases based on inclusion and exclusion criteria. 
1. The ELISA for detection of IgM antibodies to scrub typhus was validated and a 
diagnostic cut-off was determined using samples from healthy blood donors and 
patients with scrub typhus, sepsis, enteric fever, malaria and dengue. 
2. A nested PCR to detect rrs gene (547bp) of leptospira and loop mediated isothermal 
amplification (LAMP) assay to detect LipL32 and LipL41 genes of leptospira and 
IgM antibody detection by ELISA was standardised and performed. 
3. Using the case definition of leptospirosis (positive by molecular assays or those 
fulfilling the modified Faine‟s criteria) 52 patients were diagnosed as cases of 
leptospirosis. 
4. Urine output and platelet count was significantly reduced in patients with 
leptospirosis (p<0.05). Severe jaundice and renal compromise as shown by raised 
bilirubin and creatinine levels were significantly related to leptospirosis (p<0.05). 
5. Among the leptospirosis cases, 3 samples were positive by all the three tests, 2 
samples were positive only by PCR, 7 samples were positive only by LAMP assay 
and in 40 samples only  IgM antibodies to leptospira were detected  by ELISA. 
6. Using latent class analysis, PCR had a specificity of 98.64%, LAMP assay had a 
specificity of 95.24% and IgM ELISA had a specificity of 72.79% though all the three 
tests had a sensitivity of 100%. 
117 
 
7. Sequencing of two amplified products of PCR which were also LAMP positive 
confirmed the fidelity of amplification of Leptospira interrrogans.  
8. In the early phase of illness (within 7 days) LAMP assay performed better for 
diagnosis of leptospirosis whereas IgM ELISA was the mainstay of diagnosis from 
second week onwards. 
9. Among the leptospirosis patients, 22 had IgM antibodies to scrub typhus as detected 
by ELISA. It was not known whether these were cross reaction or co-infection with 
scrub typhus.  
10. The findings in this study need to be prospectively evaluated further in community 
based studies using more specific tools for confirming leptospirosis with an emphasis 
on testing paired serum samples. 
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Annexure I  
PATIENT INFORMATION SHEET 
 
Leptospirosis is a disease caused by a germ and is a widespread zoonotic disease (an animal 
disease which can also affect humans). Humans acquire this infection when they come in 
direct or indirect contact with urine of an infected animal. The infection can present as mild 
disease or very severe disease. In those with severe disease, there can be jaundice and organ 
damage in addition to the fever which is associated with a high death rate. Rapid and correct 
diagnosis is of utmost importance for starting appropriate treatment which will prevent severe 
illness and death.  
This study titled “Utility of loop-mediated isothermal amplification (LAMP) assay and 
ELISA in confirmation of leptospirosis: A pilot study” is aimed at finding out the usefulness 
of the currently used laboratory test (ELISA) and a new test (LAMP) for the diagnosis of this 
disease.  
 
You are requested to participate in this study. Your identity and the results of the tests will 
remain confidential.  
 
For the study, a blood sample will be collected at the time of your admission again 7 
days after the first sample. There is no foreseeable risk (risk of injury is very minimal) 
in participation in the study as the sample being asked for, is routinely obtained on most 
patients as part of the standard testing protocol for detection or confirmation of  the 
cause of ill-health. 
 
The result of the tests will be made known to you, if you consent to being informed. No other 
monetary or material initiative is provided for participation in the study. The tests are 
conducted free of charge and there is no provision for compensation for study related injury. 
 
Participation is voluntary and not mandatory. You can withdraw from the study at any time. 
Refusal to participate will not involve any penalty or loss of benefit to which you are 
otherwise entitled. 
 
Kindly ask questions and clear doubts before participation as some of the medical terms may 
not be familiar to you. 
 
Your participation is important and of immense value as the results of this study will be 
useful in determining the utility of  these tests for the rapid and correct diagnosis of this 
infection which can be life threatening especially in those who are very sick.  
                                
Contact: Mallika Sengupta 
               PG Registrar 
         Department of Clinical Microbiology 
         Christian Medical College, Vellore – 632004 
         Phone: 0416- 2282588                       Mobile: 9894719402 
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                                 CONSENT FORM FOR PARTICIPATION 
 
Study Title: Utility of loop- mediated isothermal amplification (LAMP) assay and 
ELISA in confirmation of leptospirosis 
 
Study Number:                                                           Hospital No: 
Subject‟s Name:  
Date of Birth / Age:  
(i) I confirm that I have read and understood the information sheet for the above study and 
have had the opportunity to ask questions.  
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected.  
 (iii) I understand that the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any further 
research that may be conducted in relation to it, even if I withdraw from the trial. I agree to 
this access. However, I understand that my identity will not be revealed in any information 
released to third parties or published.  
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
(v) I agree to take part in the above study.  
(vi) I also permit the use of the blood sample collected for assessing the usefulness of other 
tests which may be available in the near future for the detection of this or other related 
diseases.  
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative/Guardian: _______________________                      Date:  
Signatory‟s Name: _________________________________ 
Signature of the Investigator: ________________________              Date:  
Study Investigator‟s Name: _________________________ 
Signature of the Witness: _________________                                   Date: 
Name of the Witness: _________________________ 
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                                             Annexure II  
                      LEPTOSPIROSIS STUDY PROFORMA 
 
Patient Information 
Name Age Sex M / F 
Address Contact No 
Hospital No Unit: med1/ med2/ med3/ med4 
Date Sample Collected Date Convalescent Sera collected 
Occupation Veterinary doctor/ sugar cane worker/ rice paddy worker/ abbatoir 
worker/ dairy farmer/ pet shop/ sanitary worker  
Has pets Yes/ No Dogs/ cats/ others 
Exposure to flood Yes/ No Family member with leptospirosis 
Had contact with Animal caracass, excreta, urine 
Exposure to drainage water    Yes/ No OP Ward  
 
Symptoms 
Duration of fever      days Headache Yes/No Breathlessness Yes/No 
Extreme weakness Yes/No Cough Yes/No Rash  Yes/No 
Myalgia/Arthralgia Yes/No Chills Yes/No Calf muscle tenderness Y/N 
Abdominal pain Yes/No Jaundice Yes/No Decreased urine output Y/N 
Nausea/vomiting Yes/No Loose stool Yes/No Overt bleeding Yes/No 
Specify GI/ Haematuria/ Haemoptysis/ Skin/ Gum/ CNS/ Epistaxis/ vaginal 
 
Co-morbidities 
DM Yes/No CKD Yes/No CVA Yes/No Malignancy Yes/No none 
HTN Yes/No CLD Yes/No IHD Yes/No HIV Yes/No 
 
Physical Signs 
Pulse  Temperature  
Blood Pressure  Respiratory Rate  
Conjunctival Suffusion Yes/No Crepitations Yes/No 
Bilateral Pitting Pedal Oedema Yes/No Neck Stiffness Yes/No 
Icterus/ Jaundice Yes/No Signs of Dehydration Yes/No 
Abdominal Tenderness Yes/No Lymphadenopathy Yes/No 
Hepatomegaly Yes/No Splenomegaly Yes/No 
Rash Yes/No UL/ LL/ Face/ Neck/ Palms/ Soles 
Macular/Papular/Maculopapular/Vesicular/Petechial/Ecchymotic/Erythematous/Pustular 
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Diagnostics on Admission 
Haemoglobin  Na/K         / Bilirubin(D/T)          / 
TC  Bicarbonate  SGOT/SGPT          / 
Neutrophil             % Urea/creatinine        / ALP  
Lymphocyte             % Amylase/lipase        / PT/APTT         / 
Platelets  ABG pCO2/O2        / SpO2  
Urine RBC/WBC  pH  
Urine culture  CXR  
 
Malaria Pos/neg/nd Brucella IgM/IgG Pos/neg/nd Blood culture  
Widal Pos/neg/nd Scrub typhus IgM Pos/neg/nd Dengue IgM/IgG Pos/neg/nd 
Spotted fever IgM/IgG Pos/neg/nd BBV HIV/HBsAg/HCV 
ANA Pos/neg/nd Pattern Homo/speckled/nucleolar 
 
Leptospiral Test 
Leptospiral IgM ELISA Acute                 convalescent 
Leptospiral PCR  
Leptospiral LAMP  
 
Course 
Antimicrobial  Dose                                             Duration 
   
Had Any of the Following IV Fluid/ Transfusion/ Ventilatory Support/ Pacemaker/ Inotropes/ 
Dialysis 
Complications Renal Failure/ ARDS/ Massive Bleeding/ Meningitis/ Myocarditis/ 
Fulminant Hepatic Failure 
Outcome Alive/ Dead Total Stay  
Date Admitted  Date Discharged/died  
 
Pos- positive 
Neg- negative 
nd- not done 
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